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Poxviruses are large, enveloped, double-stranded DNA viruses that replicate in the 
cytoplasm of host cells and are responsible for diseases of humans and other animals. 
Vaccinia virus (VACV), the most extensively studied member in the family, encodes 
approximately 200 proteins, of which 100 are conserved in all members of the 
vertebrate subfamily of poxviruses and have roles in gene expression, DNA 
replication, morphogenesis and cell entry. Previous studies have shown that several 
vaccinia virus proteins localize to the endoplasmic reticulum (ER), suggesting that it 
serves as the source of viral membranes. Determining the topology of these viral 
proteins can provide information about protein function and viral membrane 
formation. My first project involved using an asymmetric self-associating split-GFP 
system to determine the topology of the transmembrane viral proteins L2 and A30.5 
that localize in the endoplasmic reticulum. This split-GFP system uses large (215 aa) 
  
and small (16 aa) fragments of GFP that fluoresce only upon complementation. Our 
results showed that a short GFP fragment can be used to tag small transmembrane 
viral proteins to determine their localization and topology in vivo. The second project 
focuses on a protein called I2, which I showed is required for later stage virion 
morphogenesis. I deleted the I2 gene from the VACV genome by homologous 
recombination. The I2-deletion mutant was unable to replicate in control cells 
demonstrating that the protein has an essential role in VACV replication. 
Transmission electron microscopy revealed a striking defect in virus morphogenesis. 
During normal VACV morphogenesis, spherical immature particles shed the viral 
D13 scaffold protein and assume the brick shape of mature infectious particles. 
However, this transition did not occur in cells infected with the I2-deletion mutant 
and dense spherical particles accumulated. Furthermore, the scaffold protein was 
retained on the defective particles. In addition, the levels of membrane proteins 
comprising the entry/fusion complex were greatly diminished in these particles 
although most other proteins were present at normal levels. Based on these data, I2 is 
important for removal of the scaffold protein from immature virus particles, which is 
necessary for subsequent steps in morphogenesis including the incorporation of the 
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The family Poxviridae is a group of large DNA viruses with many distinctive 
features that replicate in the cytoplasm (1). Among the family, variola virus (VARV) 
and molluscum contagiosum virus (MOCV) are obligate human pathogens. Other 
members such as monkeypox virus (MPXV) can also infect humans by transmission 
from other animal hosts. Smallpox, one of the most devastating diseases in world 
history, is caused by VARV. Beginning in 1967, the World Health Organization led 
an intensive smallpox eradication program and was able to declare eradication of the 
disease in May 1980 (2). 
Despite the eradication of smallpox, poxviruses continue to be studied for 
multiple reasons. Their threat as infectious agents is ever-present due to the cessation 
of smallpox vaccination, which has left newer generations vulnerable to bioterrorism 
involving smallpox (3). Ongoing epidemics and endemics of other poxvirus members 
are also of concern. Recently, rising numbers of MPXV infections are being reported 
in Central Africa (4). The need for continuing poxvirus research goes beyond merely 
establishing defensive measures against these threats. In 1982, the use of poxviruses 
as expression vectors was first described, and since then they have been widely used 
throughout research (5). Moreover, the development for their uses in medical 




The fascinating characteristics of poxvirus are another reason for their 
continued research. Likewise, the principle goal of this dissertation is to reveal the 
unique nature of poxvirus morphogenesis. Vaccinia virus (VACV), a prototype in 
poxvirus research, is the most extensively studied member of the family. As an 
animal virus, it was the first to be propagated in cell culture, physically purified, 
accurately titered, chemically analyzed, and observed microscopically (1). Decades of 
extensive VACV research have produced many enlightening discoveries, which also 
gave inspirations to building concepts in virus-host interactions and molecular 
biology in general. However, morphogenesis still remains one of the most poorly 
understood areas of the poxviral replication cycle (8). This dissertation focuses on 
studying proteins required for VACV morphogenesis in an effort to add another 
stepping-stone towards a solid understanding of this complicated topic. 
Chapter 3 describes the use of split-green fluorescent protein (GFP) to 
determine membrane topology of proteins associated with the endoplasmic reticulum 
(ER). Obtaining topological information can provide promising insights into protein 
interaction studies (9). Evidence suggests that ER is the source of viral membranes, 
and that multiple vaccinia proteins interact with the ER (8, 10, 11). To study how 
these proteins are oriented on the ER membrane, we adapted the split-GFP system to 
develop a simple and rapid method of determining topology. VACV morphogenesis 
proteins L2 and A30.5, previously with unknown topology, were analyzed with this 
method. Furthermore, we showed that our method can be used for non-viral (cellular) 




Chapter 4 covers a reverse genetics study on VACV protein I2, which turned 
out to have a crucial role in morphogenesis. Construction of an I2 knockout virus has 
led to striking observations including mislocalization of VACV entry/fusion proteins 
and retention of scaffold proteins on the virion surface. A large portion of this chapter 
is included in a manuscript being prepared for submission. While proteins discussed 
in chapter 3 are necessary for the early stages of morphogenesis, I2 plays a part in 
later stages of morphogenesis. Therefore, the virus morphogenesis section in 
literature review (chapter 2) will include VACV morphogenesis from early membrane 
formation stage to the later virion maturation stage, in addition to comparing each 












The family Poxviridae is a group of large enveloped double-stranded DNA 
(dsDNA) viruses, distinguished by its replication in the cytoplasm of host cells and its 
large complex virion containing a dsDNA genome of 130 to 300 kilobase pairs (kbp) 
with a hairpin loop at each end (1). Based on host range, the family is divided into 
two subfamilies Chordopoxvirinae and Entomopoxvirinae (Table 2.1). The 
subfamilies are subdivided into genera, which are classified by similarities in 
morphology and host range, as well as genetic and antigenic relatedness (1).  
The Chordopoxvirinae infect vertebrates including various species of 
mammals, birds, and reptiles (13). According to the latest virus taxonomy release 
from the International Committee on Taxonomy of Viruses (14), the 
Chordopoxvirinae are comprised of 10 genera: Avipoxvirus, Capripoxvirus, 
Cervidpoxvirus, Crocodylidpoxvirus, Leporipoxvirus, Molluscipoxvirus, 
Orthopoxvirus, Parapoxvirus, Suipoxvirus, and Yatapoxvirus (Table 2.1). Novel 
poxviruses are constantly being discovered (15-20), adding more diversity to the 




poxvirus (18) are yet to be assigned within a genus in the Chordopoxvirinae 
subfamily (Table 2.1). The Entomopoxvirinae infect insect hosts, and are further 
divided into three genera: Alphaentomopoxvirus, Betaentomopoxvirus, 
Gammaentomopoxvirus, and an unassigned group of two species (Table 2.1). 
Poxviruses are also grouped as one of the nucleo-cytoplasmic large DNA 
viruses (NCLDV), with DNA sequencing and bioinformatics suggesting distant 
relationship with Phycodnaviridae, Asfarviridae, Ascoviridae, Iridoviridae, 
Mimiviridae and Marseillevirus (21). Additional relatives that have joined the 
NCLDV group are megaviruses (22), pandoraviruses (23), and pithoviruses (24), 






Table 2.1 Taxonomy of the Poxviridae family 















Lumpy skin disease virus 
Sheeppox virus 
Cervidpoxvirus Mule deerpox virus 
Crocodylidpoxvirus Nile crocodilepox virus 
Leporipoxvirus 
Hare fibroma virus 
Myxoma virus 
Rabbit fibroma virus 
Squirrel fibroma virus 













Bovine papular stomatitis virus 
Orf virus 
Parapoxvirus of red deer in New Zealand 
Pseudocowpox virus 
Suipoxvirus Swinepox virus 
Unassigned Squirrelpox virus 
Yatapoxvirus 
Tanapox virus 






Anomala cuprea entomopoxvirus 
Aphodius tasmaniae entomopoxvirus 
Demodema bonariensis entomopoxvirus 
Dermolepida albohirtum entomopoxvirus 
Figulus sublaevis entomopoxvirus 
Geotrupes sylvaticus entomopoxvirus 
Melolontha melolontha entomopoxvirus 
Betaentomopoxvirus 
Acrobasis zelleri entomopoxvirus 
Adoxophyes honmai entomopoxvirus 
Amsacta moorei entomopoxvirus 
Arphia conspersa entomopoxvirus 
Choristoneura biennis entomopoxvirus 
Choristoneura conflicta entomopoxvirus 
Choristoneura diversuma entomopoxvirus 
Choristoneura fumiferana entomopoxvirus 
Choristoneura rosaceana entomopoxvirus 
Chorizagrotis auxiliaris entomopoxvirus 
Heliothis armigera entomopoxvirus 
Locusta migratoria entomopoxvirus 
Mythimna separata entomopoxvirus 
Oedaleus senegalensis entomopoxvirus 
Operophtera brumata entomopoxvirus 
Schistocerca gregaria entomopoxvirus 
Gammaentomopoxvirus 
Aedes aegypti entomopoxvirus 
Camptochironomus tentans entomopoxvirus 
Chironomus attenuatus entomopoxvirus 
Chironomus luridus entomopoxvirus 





Melanoplus sanguinipes entomopoxvirus 'O' 
 
Table created from data in Virus Taxonomy: 2015 Release (14), Copyright © 2017, 






The orthopoxviruses (OPXVs) are the most extensively studied genus within 
the poxvirus family. The Orthopoxvirus genus is made up of 10 species: camelpox 
virus, cowpox virus (CPXV), ectromelia virus, MPXV, raccoonpox virus, skunkpox 
virus, taterapox virus, VACV, VARV, and volepox virus (Table 2.1). The names of 
these virus species do not necessarily indicate their natural reservoir. Most of the 
names were given based on the host where the virus was initially isolated. For 
example, the natural reservoirs of CPXV and MPXV are rodents, but they were first 
isolated in cows and monkeys, respectively, hence their names (1). 
VARV the most infamous member of the OPXVs, is the causative agent of the 
smallpox disease, which made its mark as one of the most lethal diseases in human 
history (2). It is thought that for over three thousand years, smallpox spread across the 
world as human populations started to get well established and grew in numbers (25). 
Smallpox was universally feared for its high fatality rate, which was about 30% 
overall (26). The rate reached to 50% or more in very young individuals or in those 
over 40 years of age (27). In some places within Asia and Europe where old records 
exist, an average of 10% of all deaths were caused by smallpox each year (25). The 
concept of vaccines had not yet been developed, but continuous efforts were made 
throughout history to cure or prevent this threatening disease. From a historical 
perspective, these efforts became the foundation for the birth of vaccines and 
immunology (28). Prophylactic cutaneous or intranasal inoculations of smallpox scab 
material gave mild infection symptoms but ultimately prevented future lethal 




significantly to alleviate the lethality of the disease (29). In 1798, Edward Jenner 
published a safer alternative process by describing that infection with material 
obtained from the non-lethal cowpox virus infection of a dairymaid protected against 
subsequent infection with smallpox (30). The Latin word for cow is vacca and for 
cowpox is vaccinia, which led Jenner to call this process vaccination. Jenner initially 
used CPXV as vaccines against smallpox, but live VACV became the main vaccine 
used during the smallpox eradication program (29). 
VACV is very closely related to CPXV, and historically they have often been 
considered the same (31). The exact origin of VACV is unknown, with decades of 
laboratory passaging making it more difficult to trace back towards its origin (32). In 
addition to its role as the active constituent of the smallpox vaccine, VACV is the 
most extensively studied member of the poxvirus family. Its research continued 
despite the eradication of smallpox and has revealed countless characteristics of 
OPXV as a whole. 
 
2.1.3 Virion structure 
The virions of poxviruses are brick- or barrel- shaped with a membrane 
envelope around its complex structure (Figure 2.1). Unlike many other well-
characterized viruses, poxvirus virions are large in size and lack symmetry. The size 
of the virion reaches about 360 X 270 X 250 nm in dimensions, big enough to barely 





Figure 2.1 Isolated vaccinia virus particles (MV) preserved by rapid freezing and viewed by 
cryo-EM 
(A) Cryo-electron micrograph showing an image of several particles in a typical projection. 
(B) Section taken from the tomographic reconstruction of the same area as in panel A. (C) 
Four sections of a particle taken subsequently. Each section is 24 nm thick and 24 nm apart 
from each other. Scale bar measures 200 nm. Figure reprinted from Cryklaff et al. (33) with 




reveal greater detail under higher magnification (34, 35). There are several forms of 
infectious virions that vary mainly by the number of outer membrane layers, and they 
will be discussed in more detail later. The basic infectious form is the mature virion 
(MV), and it is the most abundant form produced during replication. MVs bear a 
single outer lipid membrane bilayer that is 5-6 nm thick (33), containing a dumbbell-
shaped core and two lateral bodies within the cavities (1). Current techniques 
including EM and cryoelectron tomography are not sufficient to fully resolve the 
complex core structure, but suggest that the core wall has two layers surrounding the 
nucleoprotein (33). VACV MV is primarily composed of protein (90%), lipid (5%), 
and DNA (3.2%) by dry weight (36), with a overall mass of 5-10 femtogram (37, 38). 
Additionally, other components such as spermine, spermidine, and signs of RNA 
presence have been found in VACV MV (39, 40). 
 
2.1.4 Genome organization 
Poxviruses have large, linear dsDNA genomes that range from 130 to 300 kbp 
(1). The large size of the genome gives these viruses the capacity to encode numerous 
genes, with VACV containing more than 200 open reading frames (ORFs) in its ~195 
kbp genome (41). At the ends of poxvirus genome there are regions called inverted 
terminal repetitions (ITRs), which are identical sequences but oriented in opposite 
directions at each end (Figure 2.2)(42). ITRs contain hairpin loops that connect the 
dsDNA at the very end of the genome, these loops are A/T rich and incompletely 





Figure 2.2 Diagram of vaccinia virus genome with HindIII restriction sites (44)  
The VACV genome has various insertions sites, annotated with blue lines, where foreign 
genes can be inserted. ITRs: inverted terminal repeats; VGF: VACV growth factor gene; N2, 
M1: N2 and M1 genes; RR: ribonucleotide reductase gene; TK: thymidine kinase gene; 14K: 




(46) and sets of short tandemly repeated sequences (47). Variations such as 
duplications, deletions, and transpositions can alter the size of ITRs (48-50). 
While variable genes involved in host interactions are located near the ends of 
the genome, the central region of the genome contains many of the highly conserved 
genes that are essential for viral replication (1). Almost 50 genes are conserved 
among all poxviruses including entomopoxviruses (Table 2.2), and about 50 
additional genes are conserved in just chordopoxviruses (Table 2.3)(51). Most of the 
genes do not overlap and each is regulated by an early, intermediate or late promoter 
that is recognized by their respective transcription factors. 
 
2.1.5 Gene nomenclature 
The convention for naming VACV ORFs originated before whole genome 
sequencing was available (1). Poxvirus genomes can be digested with HindIII 
restriction endonuclease, generating fragments that could be separated as a ladder 
using agarose gel electrophoresis (Figure 2.3). A letter was assigned to each fragment 
from largest fragment ‘A’ to smallest fragment ‘O’ in alphabetic order (52). The 
ORFs contained within each HindIII fragment were assigned a number starting from 
1, in accordance to their position in the genome from left to right, and the letter L or 
R to indicate the gene orientation. Each ORF name therefore consisted of the 
fragment letter, the ORF number, and its transcriptional direction L or R (this is 
dropped in polypeptide names) (1). For example, L2R gene is the 2nd ORF in the 
HindIII L fragment and is transcribed from left to right (R). The protein encoded by 




the other end is available, but the traditional letter names are still used widely in 





Table 2.2 Completely conserved gene families of Poxviridae 
VV-Cop 
ORF 
Family names of 49 poxvirus conserved genes Family identification 
no. 
Functiona 
A1L Late transcription factor 2 (VLTF-2) 1153 T 
A2L Late transcription factor 3 (VLTF-3) 1228 T 
A3L P4b precursor 1072 M 
A5R RNA polymerase subunit 19 (RPO19) 1225 T 
A7L Early transcription factor—large (VETF-l) 914 T 
A9L Late virion membrane protein (MP), essential 1218 M 
A10L P4a precursor 1750 M 
A11R Unknown 1217 U 
A16L Unknown soluble-myristylated 887 U 
A18R DNA helicase, transcription 896 T 
A21L Unknown 1202 U 
A22R Holliday junction resolvase 1201 R 
A23R Intermediate transcription factor 3—large (VITF-3) 946 T 
A24R RNA polymerase subunit 132 (RPO132) 880 T 
A28L Unknown predicted signal peptide 1099 U 
A29L RNA polymerase subunit 35 (RPO35) 1197 T 
A32L ATPase-DNA packaging protein 1192 M 
D1R mRNA capping enzyme large subunit 1109 T 
D4R Uracil-DNA glycosylase 1130 R 
D5R NTPase, DNA replication 950 R 
D6R Early transcription factor—small (VETF-s), 
morphogenesis 
1027 T, M 




D11L Nucleophosphohydrolase I (NPH-I), virion 1093 T, M 
D12L mRNA capping enzyme small subunit, VITF 1151 T 
D13L Rifampin resistance MP, morphogenesis 883 M 
E1L Poly(A) polymerase large subunit 939 T 
E6R Unknown 1253 U 
E9L DNA polymerase 910 R 
E10R Redox-EVR-1, morphogenesis 900 M 
F9L Unknown predicted MP 1001 U 
F10L Serine-threonine kinase, morphogenesis 1065 M 
G1L Protease morphogenesis 1275 M 
G5R Unknown 1017 U 
G6R Unknown 1131 U 
G9R Myristylated protein 957 U 






Family names of 49 poxvirus conserved genes Family identification 
no. 
Functiona 
H3L Intracellular mature virus morphogenesis viral 
protein (VP55) 
1269 M 
H4L RNA polymerase-associated protein (RAP94) 1695 T 
H6R Topoisomerase type I 908 R 
I7L Virion core protease 1015 M 
I8R RNA helicase, NPH-II 1104 T 
J3R Poly(A) polymerase small subunit VP39 895 T 
J5L Late MP, essential 1777 M 
J6R RNA polymerase subunit 147 (RPO147) 1040 T 
L1R Myrisylated MP virion 1044 M 
L3L Unknown 1285 U 
L4R Core packaging transcription 1283 T, M 
L5R Unknown predicted MP 1511 U 
 
a T, transcription; M, morphogenesis; U, unknown; R, replication. Table reprinted from 






Table 2.3 Conserved gene families in Chordopoxvirinae 
VV-Cop 
ORF 





A2.5L Thioredoxin-like protein 1552 M 
A4L Core protein 1580 M 
A8R Intermediate transcription factor 3—small (VITF-
3) 
1758 T 
A6L Unknown 1224 U 
A12L Structural protein 1216 M 
A13L Virion membrane protein (MP) 1575 M 
A14L Intracellular mature virus (IMV) phosphorylated 
MP 
1323 M 
A14.5L IMV MP, virulence factor 1547 M 
A15L Unknown 1546 U 
A17L IMV phosphorylated MP 1206 M 
A19L Unknown 1545 U 
A20R DNA polymerase processivity factor 1203 R 
A30L Virion morphogenesis 1561 M 
A34R Extracellular enveloped virion glycoprotein 1540 M 
D2L Structural protein 1351 M 
D3R Structural protein 1350 M 
D9R mutT motif, nucleoside triphosphate 
pyrophosphohydrolase 
1142 U 
E2L Unknown 1251 U 
E4L RNA polymerase subunit 30 (RPO30), VITF-1 1252 T 
E8R Endoplasmic reticulum-localized MP 1254 U 
F12L Actin tail, microtubule 1145 M 
F13L Phospholipase extracellular enveloped virion 1146 M 
F15L Unknown 1148 U 
F17R DNA-binding phosphoprotein 1150 R 
G2R Late transcription factor (VLTF) 1277 T 
G3L Unknown 1521 U 
G4L Glutaredoxin 2 1279 M 
G5.5R RNA polymerase subunit 7 (RPO7) 1133 T 
G7L Structural protein 1776 M 
G8R Late transcription factor 1 (VLTF-1) 1287 T 
H1L Tyrosine-serine phosphatase 1270 M 
H5R Late transcription factor 4 (VLTF-4) 1353 T 
H7R Unknown 1260 U 
I1L DNA-binding protein 1263 R 
I2L Unknown 1598 U 











I5L Unknown VP13 1367 U 
I6L Unknown 1268 U 
J1R Virion 1273 M 
J4R RNA polymerase subunit 22 (RPO22) 1272 T 
L2R Unknown 1584 U 
 
a T, transcription; M, morphogenesis; U, unknown; R, replication. Table reprinted from 






Figure 2.3 HindIII restriction fragments of poxvirus genomes 
DNA fragments generated from rabbitpox strain Utrecht (RP); vaccinia strain DIE, Hall 
Institute (HI), Lister (LS), or Western Reserve (WR); monkeypox strain Congo (MPC), 
Denmark (MPD), or España (MPE); variola strain Butler (BUT) or Harvey (HAR); cowpox 
red strain Austria (AR), Brighton (BR), Ruthin (RR), or Daisy (DR); and ectromelia strain 
Hampstead (EH) or Moscow (EM). Fragments were separated by agarose slab gel 
electrophoresis. Arrows show size heterogeneity of fragment B,C, and G of indicated strains. 





2.2 Poxvirus Replication 
2.2.1 Attachment and entry 
VACV cell attachment and entry is the crucial first step in initiating the entire 
viral replication cycle (Figure 2.4). VACV can enter into many different types of 
mammalian cells. The entry mechanisms vary based on the type of infectious virion 
forms (1). Two infectious forms exist, with MVs being more common than enveloped 
virions (EVs). MVs have a single outer membrane, but EVs have an additional 
membrane layer surrounding the MV form (Figure 2.5)(54). The additional 
membrane has at least six different proteins not present on the MV outer membrane, 
and this extra layer may provide additional resistance to antibody neutralization (55). 
MVs are believed to be important for animal-to-animal spread, while EVs are 
important for cell-to-cell spread (1). 
Once the MV attaches to the cell, the virus core can enter by either direct 
fusion with the plasma membrane or following endocytosis (1). Entry via the 
endocytic route is promoted by low pH through endosomal acidification. Unlike 
many other enveloped viruses that encode merely one or two proteins for attachment 
and fusion, VACV encodes at least four attachment and 11 entry/fusion proteins 
(Table 2.4). A26, A27, D8, and H3 mediate attachment by binding cell surface 
glycosaminoglycans and laminin (1). A26 binds laminin, A27 and H3 bind heparin 
sulfate, and D8 binds chondroitin sulfate (56-59). Among the four attachment 
proteins, only D8 and H3 have transmembrane domains, while A26 and A27 are held 






Figure 2.4 Replication cycle of orthopoxviruses 
Infection cycle is initiated when an infectious form of the virion, such as MV or EV, attaches 
and enters the cell. As soon as entry occurs the early mRNAs are released and translated to 
produce proteins necessary for host immune defense, DNA replication, intermediate 
transcription, etc. Once DNA is replicated, intermediate gene expression can occur, followed 
by late gene expression. Proteins produced post-replication include structural and 
morphogenesis proteins that assemble viral membranes into immature virions (IVs). IVs go 
through maturation and MVs, the first infectious form, are produced. The MVs can further 
acquire an additional double membrane to become wrapped virions (WV) through wrapping 
of trans-Golgi network (TGN) or endosomal membranes. The WV outer membrane fuses 
with the plasma membrane as the virion leaves the cell in EV form. Illustration kindly 





Figure 2.5 Two major forms of infectious vaccinia virions 
The major difference between MVs and EVs is the presence of an additional outer membrane  
(red) on EVs. This additional membrane, annotated as EV membrane, contains six distinct 
proteins. The MV membrane, present in both MVs and EVs, contains about 20 proteins, 
including EFC proteins that mediate attachment and entry. Figure reprinted with permission 




Fusion and core entry of VACV require a set of transmembrane proteins that 
form a complex known as the entry/fusion complex (EFC) on the MV membrane 
(Figure 2.5). The EFC is composed of 11 proteins: A16, A21, A28, F9, G3, G9, H2, 
J5, L1, L5, and O3 (54, 55, 61-75). Properties of each protein are listed in Table 2.4. 
Every member of the EFC is essential for entry and conserved in poxviruses, 
suggesting a common entry mechanism is used across the family (61). Repression of 
each entry/fusion protein does not affect assembly of virions, which appear normal by 
EM, but the virions are not able to enter new cells (1). With the exception of L1 and 
F9, absence of a single member in the EFC can cause the whole complex to 
breakdown. Thus, L1 and F9 are occasionally referred to as EFC-associated proteins. 
Protein I2 had also been implicated as a potential entry/fusion protein for the past few 
years, but it will be discussed later in chapter 4 that I2 is rather a viral morphogenesis 
protein. 
Understanding the entry mechanism has faced many hurdles due to a lack of 
information including detailed structures and protein-protein interactions of 
entry/fusion proteins. Nevertheless, fusion of the MV membrane with the plasma 
membrane has been demonstrated (76, 77) and a few protein-protein interactions of 
entry proteins have been identified (74, 78, 79). EVs enter cells in a similar fashion to 
MVs. EVs shed their outermost membrane as they attach to the cell, so that the 
subsequent membrane (MV membrane) may undergo fusion with the plasma 
membrane. They may also enter by macropinocytosis (80), a regulated form of 






Table 2.4 Vaccinia virus attachment and entry/fusion proteins 
Protein kDa TMa S-Sb Conservedc Properties 
Attachment proteins 
A26 58 – – – Binds laminin; associates with A27; interacts with A16 and G9; fusion suppressor 
A27 13 – – – Binds heparan; associates with A26 and A17 membrane protein; Ntd 
D8 35 N – – Binds chondroitin; Nt 
H3 38 C – P Binds heparan; Nt 
 Entry-fusion complex 
A16 43 C + P 
Homolog G9 and J5; interacts with G9 and 
A26; complex with G9 interacts with A56:K2 
complex 
A21 14 N + P  
A28 16 N + P Interacts with H2; Nt 
F9 24 C + P  
G3 13 N  P Interacts with L5 
G9 39 C + P 
Homolog A16 and J5; interacts with A16 and 
A26; complex with A16 interacts with A56:K2 
complex; Myre 
H2 22 N + P Interacts with A28 
J5 15 C + P Homolog A16 and G9; Myr 
L1 27 C + P Myr; Nt 
L5 15 C + P Interacts with G3 
O3 4 N  C Smallest VACV protein 
 
a TM, N- or C-terminal transmembrane domain. b S-S, intramolecular disulfide bond(s). c 
Conserved in all poxviruses (P) or all chordopoxviruses (C). d Nt, target of neutralizing 




2.2.2 Viral gene expression 
VACV genes can be classified as early, intermediate, or late based on their 
temporal regulation (1). Expression stages within the replication cycle are annotated 
in Figure 2.4. Early transcripts are synthesized from a single entering genome prior to 
viral DNA (genome) replication. It is only after DNA replication that intermediate 
and late genes can be transcribed, thus often getting grouped together and referred to 
as post-replicative genes. Deep sequencing of the VACV transcriptome has detected 
RNAs of 118 ORFs before viral DNA replication and 93 ORFs post-replication (81). 
Cytosine arabinoside (AraC), a DNA replication inhibitor drug, is commonly used in 
poxviral studies to limit viral expression to early genes. 
The virus encodes stage-specific transcription factors that function with the 
conserved early, intermediate, or late promoter sequences (82-84). Generally, early 
transcripts encode factors and enzymes for DNA replication, intermediate stage 
transcription, and host defense inhibition. Intermediate and late transcripts encode 
factors necessary for later steps of replication, such as virion assembly. Additionally, 
intermediate mRNAs encode factors for late gene expression, and late mRNAs 
encode early transcription machinery to be packaged into newly formed virions (1). 
The early transcription factors and RNA polymerase are packaged in progeny 
virions along with other enzymes (85), which allows for immediate synthesis of early 
mRNA. Virus cores are transported to transcription sites on microtubules (86, 87) and 
start production of mRNAs within minutes after entry. Capped, polyadenylated and 
methylated mRNAs are produced by this early transcription system (88-91). The 




(VETF), DNA-dependent RNA polymerase, RNA polymerase-associated protein of 
94-kDa (RAP94), poly(A) polymerase, nucleotide phosphohydrolase I (NPH I), 
topoisomerase, and enzymes for capping and methylation (1). VETF is a heterodimer 
of 82 and 74 kDa subunits, respectively encoded by late genes A7L and D6R (92-94). 
VETF interacts with RAP94, another late protein encoded by H4L gene (85). RAP94 
is associated with RNA polymerase and confers promoter specificity for early gene 
transcription (95-97). There are eight subunits in the VACV RNA polymerase with 
seven of them being homologs of cellular RNA polymerase (98-108). Unlike VETF 
or RAP94, subunits of RNA polymerase are encoded by early genes as they are also 
needed for intermediate and late mRNA synthesis. VETF, RAP94, RNA polymerase, 
NPH I, and capping enzyme form a complex for accurate transcription and 
termination of early genes (109, 110). 
Intermediate transcription requires RNA polymerase along with three VACV 
intermediate transcription factors: VITF-1, VITF-2, and VITF-3 (1). The E4 gene 
encodes VITF-1, which also serves as a subunit for RNA polymerase (107). VITF-2 
is a cellular factor (111), and transcripts from A8R and A23R genes encode the 
components of VITF-3 (112). The list of intermediate gene products has been 
recently expanded to 53 genes (113), including three of four VACV late transcription 
factors (VLTFs) G8R, A1L, and A2L respectively encoding VLTF-1, VLTF-2, and 
VLTF-3 (114). Additionally, the H5R gene product VLTF-4 was shown to have a 
role in late transcription and to interact with other VLTFs (115, 116). 38 genes have 
been identified as late stage genes, including many of the MV membrane and 




VACV temporal regulation of transcription is not solely dependent on 
sequential synthesis of mRNA. Transcripts from each stage decline rapidly, usually 
with half-lives of 30 min or less, which may ensure apparent distinction between the 
expression stages (117-120). Decapping enzymes encoded by D9R and D10R genes 
promote degradation of viral mRNAs, as decapped mRNAs are vulnerable to cellular 
5’ exonuclease digestion (1, 121-124). D9 and D10’s activity is not limited to viral 
mRNAs but includes cellular mRNAs (125), possibly contributing to shutoff of host 
protein translation. Unlike early transcription, the intermediate and late transcription 
systems lack accurate termination, often generating variable lengths of 3’ end on their 
mRNAs (126). Overextended mRNAs are subject to overlapping with transcripts 
from other ORFs, increasing the possibility of generating double-stranded RNAs 
(dsRNAs). Host innate defense proteins such as protein kinase R (PKR) or 2’5’-
oligoadenylate synthetase (OAS) can be stimulated by dsRNAs to trigger antiviral 
responses (127-129). Mutations in catalytic sites of both D9 and D10 lead to 
accumulation of dsRNA, stressing the importance of decapping during VACV 
infection (130). 
 
2.2.3 Viral genome replication 
Poxviruses are distinguished from most DNA viruses as they replicate their 
dsDNA genome in the cytoplasm (Figure 2.4). DNA replication foci, often called 
viral factories (Figure 2.6), are detectable in the cytoplasm using microscopy (131-
133). Multiple VACV proteins involved in DNA replication have been found with 





Figure 2.6 Vaccinia virus factories in cytoplasm of an infected cell 
Confocal microscopy images of a HeLa cell with simultaneous infection of two recombinant 
VACVs, expressing either cyan fluorescent protein (CFP) or yellow fluorescent protein 
(YFP)-tagged A5 core protein. Blue is 4’,6-diamidino-2-phenylindole (DAPI) staining of 
nucleus (N) and virus factories (F). Two virus factories arose in a single cell from different 




encodes a protein with both nucleoside-triphosphatase (NTPase) and primase activity 
(137-142), B1R encodes serine/threonine protein kinase (143-145), and D4R encodes 
uracil DNA glycosylase (146). B1 kinase activity is important for blocking a cellular 
cytoplasmic protein that potentially inhibits poxviral DNA replication (147, 148). 
Another substrate protein for B1 kinase is encoded by the H5R gene (149), which 
appears to have multiple functions in DNA replication, transcription, mRNA 
processing, and morphogenesis (1). In addition, the A20R gene product is required 
for processive DNA polymerase activity (150-153). A20 was shown to interact with 
D4, D5 and H5 (154), suggesting that these proteins can form a complex (153). A 
single-stranded DNA binding protein encoded by the I3L gene (155-157) is also 
suggested to participate in DNA replication, but its exact role remains yet to be 
understood (158). 
 VACV replicative intermediates have genomes linked in head-to-head or tail-
to-tail manner (159, 160), which are referred to as concatemers. VACV Holliday 
junction resolvase, encoded by the A22R gene, cleaves the concatemers into single 
genome units (161, 162).  
Two different models have been proposed for poxvirus DNA replication, one 
is the self-priming model taken from the rolling hairpin strand-displacement method 
in the parvovirus replication model. This model was proposed due to the similarity of 
VACV genome and concatemers with parvovirus replication intermediates (158). 
More recently, reports of primase and DNA ligase requirements have rekindled the 
possibility of the semi-discontinuous leading-lagging strand synthesis model (163) for 




also contains an archaeoeukaryotic primase domain in the N-terminus essential for 
DNA replication (141, 142). The DNA ligase requirement was evident as presence of 
either viral ligase encoded by the A50R gene or host DNA ligase I was necessary 
(165). Furthermore, a recent study using deep sequencing has mapped VACV 
replication origins at the nucleotide level and supported the involvement of RNA-
primed, semi-discontinuous synthesis model of VACV DNA replication (166). 
 
2.2.4 Virion maturation and egress 
Electron microscopy of VACV-infected cells has shown multiple viral forms 
during different stages of maturation (Figure 2.7). The lower magnification electron 
micrograph in Figure 2.8 provides a comprehensive view of all the different forms 
contained within a single infected cell. Pieces of crescent-shaped membranes are the 
first viral membrane structures observed during infection. The crescents are found in 
the virus factories and they serve as starting materials that enlarge to become IVs, 
which then mature into MVs (167-169). MVs are the first mature form that is 
infectious, but it may obtain two additional membranes through wrapping of trans-
Golgi or endosomal cisternae (170-172) to become wrapped virions (WVs). As the 
WVs egress the cell, the outermost membrane fuses with the plasma membrane, 
releasing the virus to the extracellular space in the EV form (Figure 2.4). The 
morphogenesis steps between different VACV forms will be discussed in greater 
detail later in ‘Virus Morphogenesis’ section (subsection 2.3.1). 
As viral genome replication occurs before virion assembly, replicated genomes 





Figure 2.7 Forms of vaccinia virus in different maturation stages 
Transmission electron micrographs showing a closer look at a crescent (C), immature virion 
(IV), nucleoid (Nu), mature virion (MV), wrapped virion (WV), and extracellular enveloped 




microscopy has detected dense DNA entering through the virion membrane just 
before IVs completely close (173). An example of a nucleoid is shown in Figure 2.7. 
DNA accumulated as crystalloids in the cytoplasm when the drug rifampicin was 
used to inhibit IV formation (174). Gene products from A32L (175), I6L (176), and 
A13 (177) are suggested to be required for DNA packaging, although the mechanism 
is unknown. In addition to genomes, core proteins including the early transcription 
system need to be packaged in the virions as well. An electron dense mass of core 
proteins called ‘viroplasm’ gets surrounded by the crescents and enclosed as crescents 
grow into IVs (1). Viroplasm resembles the interior of IVs during normal infection, 
but accumulates into massive inclusion when virion assembly is blocked (178). 
Virion maturation requires intramolecular disulfide formation or proteolytic 
processing of some virion proteins. The disulfide bond formation of some MV 
membrane proteins is critical, as repression of any one of viral redox proteins A2.5, 
E10, and G4 leads to a block in virion maturation (179-182). Five core proteins A3, 
A10, A12, G7, L4, and a membrane protein A17 are processed (1), and there are 
probably more that have not yet been identified. Core or membrane proteins in the 
IVs are unprocessed, whereas MVs contain processed proteins. The I7L gene encodes 
the protease responsible for cleaving these proteins at a consensus AGêX site (183, 
184). Another viral protein encoded by the G1L gene has a metalloprotease motif, but 
its relevance with the processing of known proteins could not be demonstrated (185). 
I7 protease activity is also important for MV membrane morphogenesis, which will 




 While release of MV forms can only occur by cell lysis, VACV can 
alternatively egress the cell in EV forms without lysis. Some MVs get wrapped to 
become WVs, which can migrate to the cell surface. WVs travel on microtubules for 
long-range intracellular movement (186-188), involving proteins encoded by the 
A36R and F12L ORFs. The A36 and F12 proteins are present only on WV 
membranes (1). Interaction between A36 and a microtubule motor protein kinesin 
(189, 190), and the structural similarity between F12 and kinesin light chain (191, 
192) have stressed their roles in microtubular movement. As WVs reach the cortical 
actin network at the cell periphery, A36 is phosphorylated to regulate the transition 
from microtubule- to actin-based motility (193). Then the outermost membrane of 
WV fuses with the plasma membrane, exposing the EV form to extracellular space. 
A33, A34, and A36 proteins facilitate cell-to-cell spread of EVs by supporting 





Figure 2.8 Vaccinia virus infected cell 
Electron micrograph of a RK-13 (rabbit kidney) cell infected with VACV at low 
magnification. Abbreviations: C, crescent; IV, immature virion; Nu, nucleoid; MV, mature 
virion; WV, wrapped virion; EV, enveloped virion; N, nucleus. Scale bar: 2 µm. Image 




2.3 Vaccinia Virus Morphogenesis 
2.3.1 Overview 
Morphogenesis is defined as the origin and development of structural 
characteristics (198). It is one of the fundamental biological processes in development 
of many life forms, and this includes viruses. Various families of viruses have unique 
shapes acquired by their intricate morphogenetic processes. Some viruses are non-
enveloped, meaning they lack a phospholipid membrane bilayer and are shaped by 
capsid proteins that surround them. Poxviruses, however, are enveloped viruses, 
meaning their morphogenesis is largely dependent on phospholipid membranes. 
Although viral membrane morphogenesis is a part of the poxvirus replication cycle 
discussed in the previous section, morphogenesis of VACV crescents to MVs will be 
discussed separately in this section in greater depth, as this is an important topic for 
studies covered in subsequent chapters. 
 
2.3.2 Crescent and immature virion morphogenesis 
Crescents are the first detectable membrane structure of VACVs with free 
open ends in the cytoplasm (Figure 2.7). No apparent connection was observed 
between the crescents and the membranes of cellular organelles, leading to the notion 
that crescents were synthesized de novo (199). Other hypotheses proposed that 
cellular organelles are origins of viral membranes in the form of flattened cisternae, 
which have double-membranes (200, 201). However, questions arose as other studies 




membrane was confirmed by subsequent electron tomography images (202, 203). 
More recently, a connection between the endoplasmic reticulum (ER) and the viral 
membranes was demonstrated through multiple VACV knockout mutants (Figure 2.9), 
which led to a break-through in understanding VACV membrane morphogenesis 
(178). 
A group of VACV proteins conserved in chordopoxviruses, termed VMAPs 
(viral membrane assembly proteins), are essential in the early steps of morphogenesis 
(8). The up-to-date members of the VMAPs are A6 (204, 205), A11 (10, 206, 207), 
A30.5 (8) , H7 (208, 209), and L2 (11, 210, 211). All VMAPs are post-replicative 
proteins except for L2, which is expressed early. L2 and A30.5 interact with each 
other, and they both co-localize to the ER membrane with or without infection (8, 11). 
A6 and A11 have also been shown to interact, which proved to be important for the 
association of A11 with viral factories and membranes (207). The crystal structure of 
H7 was recently reported, revealing a novel phosphoinositide binding site necessary 
for viral replication (212). 
Other morphogenesis proteins include A17, A14, and D13, which are major 
constituents of crescents and IVs. A17 and A14 are transmembrane proteins that 
interact with one another; each interrupt morphogenesis when individually repressed 
(213-216). A recent report on A17 (217) has suggested its resemblance to reticulons, 
a class of membrane proteins involved in morphogenesis of tubular ER (218). D13 is 
another essential protein for morphogenesis, forming a honeycomb lattice comprised 





Figure 2.9 Vaccinia virus crescents and IV-like structures associated with ER 
Electron micrograph showing HeLa (A) and RK-13 (B through F) cells infected with 
vΔA30.5. IV-like structures cluster within ER membranes, and crescents (asterisks) are 
continuous with the ER membrane. Arrowheads: ER membrane; arrows: spicules. Respective 





not have a transmembrane domain, it interacts with the N-terminus of A17 to 
associate with viral membranes (221, 222). Cryo-electron tomography and X-ray 
crystallography revealed the structure of the D13 trimers, which have double beta-
barrel subunits arranged as pseudo-hexagonal trimers. (223-225). The coating by D13 
scaffold protein presumably confers the curvature and spherical shaping of crescents 
and IV membranes.  
Characterization of an L2-deletion mutant was the break-through study that 
first gave evidence of a direct connection of viral membranes with ER membranes 
(211). Analysis of the A30.5 protein and its deletion mutant have provided additional 
images of the connection (Figure 2.9)(8). The mutants lacked IVs and MVs but 
crescent structures were continuous with the ER and clusters of empty IV-like 
particles were observed within the ER lumen. The interior of IV-like particles did not 
contain dense core materials, which accumulated to form large masses of dense 
viroplasm. An A11-inducible mutant has also generated similar phenotypes (10), but 
detection of such structures has not yet been reported for either A6 or H7 mutants 
(178). 
Based on these novel observations, a model for viral membrane formation 
using ER membranes was proposed as illustrated in Figure 2.11 (8, 178). This model 
postulates that VMAPs, presumably with cellular proteins, generate or stabilize 
ruptures of the ER membrane. The resulting membrane segment/crescent is stabilized 
by capping of L2, A30.5, and A11 on the free ends and fuses with additional 





Figure 2.10 D13 honeycomb lattice of vaccinia virus IVs 
3-D deep-etch electron microscope image of immunogold-labeled IVs. Antibody against a V5 
epitope at the N-terminus of D13 was used. Gold particles around the sections of IV 
membranes are shown white (or bright yellow) as the contrast was reversed. Yellow scale bar 
in the bottom right measures 100 nm. Image adapted and modified from Szajner et al. (220) 





contains A14 and A17 with the latter acting as a clamp for D13 scaffold, giving 
curvature to the viral membrane. Figure 2.11 also depicts viral membrane formation 
in the absence of L2, A30.5, or A11, in which the crescent precursors containing A14 
and A17 are continuous with the ER membrane. Incomplete ruptures may still allow 
D13 to enter the ER lumen and build a scaffold around the precursors, resulting in IV-
like particles lacking cores. Failure to generate proper membrane fragments leads to 
mass accumulation of unattended core proteins (viroplasm) (178). 
 
2.3.3 Mature virion morphogenesis 
The morphologic transition from an IV to an MV is dictated by removal of the 
D13 scaffold from the IV membrane (219, 226, 227). As mentioned previously, 
scaffolding by D13 trimers hold IVs in a spherical form (Figure 2.7). When the D13 
coat is removed during maturation, virions lose the spherical morphology and become 
brick- or barrel-shaped MVs (Figure 2.1 and 2.7). Disassociation of the D13 scaffold 
from the viral membrane is dependent on I7 protease activity (221). As discussed 
before, the I7 protease is responsible for processing multiple viral proteins including 
A17. The interaction between D13 and the N-terminus of A17 is lost following the 
proteolytic processing (221), with both N- and C-terminal ends of A17 cleaved by I7 
(184, 228-230). Defects occurred in IV to MV morphogenesis when I7 expression 
was repressed, failing to disassemble the D13 scaffold from the particles (221). 
Likewise, A9 repression (231) or A6 mutation (204) resulted in a similar outcome. In 
addition to the change in outer membrane shape, the core transforms into a more 




from IV to MV (Figure 2.7). In chapter 4, a study on VACV protein I2 revealing its 





Figure 2.11 Model for vaccinia virus crescent and IV membrane formation 
Diagram showing models for viral membrane formation during infection in the absence of 
VACV L2, A30.5, or A11 (left), compared to infection with wild-type VACV (right). 
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Chapter 3: Investigating topology of ER-associated cellular 





The split GFP system was adapted for investigation of the topology of ER-
associated proteins. A 215 amino acid fragment of GFP (S1-10) was expressed in the 
cytoplasm as an unfused protein or fused to the N-terminus of calnexin and in the ER 
as an intraluminal protein or fused to the C-terminus of calnexin. A 16 amino acid 
fragment of GFP (S11) was fused to the N- or C-terminus of the target protein. 
Fluorescence occurred when both GFP fragments were in the same intracellular 
compartment. After validation with the cellular proteins of known topology (PDI and 
tapasin), we investigated two vaccinia virus proteins (L2 and A30.5) of unknown 
topology that localize to the ER and are required for assembly of the viral membrane. 
Our results indicated that the N- and C-termini of L2 faced the cytoplasmic and 
luminal sides of the ER, respectively. In contrast both the N- and C-termini of A30.5 
faced the cytoplasm. The system offers advantages for quickly determining the 
topology of intracellular proteins: the S11 tag is similar in length to commonly used 
epitope tags; multiple options are available for detecting fluorescence in live or fixed 
                                                
1 Adapted from reference 12. Hyun SI, Maruri-Avidal L, Moss B. 2015. Topology of 
Endoplasmic Reticulum-Associated Cellular and Viral Proteins Determined with Split-GFP. Traffic 




cells; transfection protocols are adaptable to numerous expression systems and can 
enable high throughput applications. 
 
3.2 Introduction 
Membrane protein topology provides important information needed to 
understand protein function and intermolecular associations. Although great strides 
have been made in predicting topology, experimental confirmation is usually required 
(232). Assays based on glycosylation (233), protease susceptibility (234), 
fluorescence (235, 236) and luciferase activity (237, 238) have provided researchers 
with options to determine the topology of transmembrane proteins. Here we describe 
a rapid, broadly applicable approach that can be used to determine the cytoplasmic 
and luminal locations of the N- and C-termini of proteins that associate with the 
endoplasmic reticulum (ER).  
The GFP from the jellyfish Aequorea victoria exhibits bright green 
fluorescence when exposed to light in the blue to ultraviolet range. Many 
modifications of GFP have been made including the division into separate fragments 
that fluoresce upon association with one another (239). One version of the split-GFP 
consists of self-assembling fragments of 215 amino acids comprising b-strands 1-10 
(S1-10) and 16 amino acids comprising b-strand 11 (S11) (240). Recently, the system 
was used for in vivo localization of proteins in protozoan and plant plastids (241-243) 
and the Escherichia coli inner membrane (244). Kaddoum et al. (245) described a 
procedure for localizing proteins tagged with S11 by incubating fixed and 




fluorescence. A tripartite version of split GFP was developed for detection of protein-
protein interactions (246). Here we show that the S1-10 domain can be selectively 
targeted to cytoplasmic and ER compartments permitting rapid determination of the 
topology of proteins fused to S11 at the N- or C-terminus in live or fixed mammalian 
cells. This split-GFP method for determination of topology differs substantially from 
the procedure used by Wright and co-workers (236) in which a cytoplasmic full-
length fluorescent protein interacts with an affinity-tagged cytosolic domain of an ER 
protein and from other approaches that use redox-sensitive (247) or glycosylatable 
(248) forms of GFP to differentiate cytoplasmic and ER luminal compartments. 
 
3.3 Materials and Methods 
3.3.1 Cells and viruses 
RK-13 cells were grown in Dulbecco’s minimum essential medium or in 
essential medium with Earle’s balanced salts, containing 10% fetal bovine serum 
(FBS; Sigma-Aldrich), 100 units penicillin, and 100 µg streptomycin per ml (Quality 







Figure 3.1 Schematic showing application of the split-GFP system for determination of the 
topology of ER membrane proteins 
(A) The large S1-10 and small S11 fragments of GFP fluoresce upon association. (B) 
Fluorescence occurs if the S11 tag on the protein of interest is in the cytoplasm when co-
expressed with Cyto-S1-10 or in the ER lumen when co-expressed with ER-S1-10. (C) 
Fluorescence occurs when the S11 tag on the protein of interest is in the cytoplasm when co-





Anti-GFP rabbit polyclonal antibody (pAb) was obtained from Invitrogen 
(Cat. A11122). The mouse MAb to PDI was from Enzo Life Sciences (Cat. ADI-
SPA-891). Anti-actin rabbit pAb was from Sigma (Cat. A2066). 
 
3.3.3 Construction of plasmids 
pCMV-mGFP 1-10 and pCMV-mGFP Cterm S11 were obtained from Sandia 
Biotech. The open reading frames (ORFs) of mGFP 1-10 (S1-10) and mGFP Cterm 
S11 (S11) were amplified from the plasmids by PCR, which were then used for 
cloning. Plasmid Cyto-S1-10 was constructed by fusing the VACV synthetic 
early/late promoter (250) to the S1-10 ORF. Expression of the other S1-10 fusion 
constructs was also regulated by the VACV synthetic early/late promoter. Plasmid 
ER-S1-10 was made by fusing the signal peptide sequence 
MGWSCIILFLVATATGAHS to the N-terminus of S1-10 and the ER retention signal 
peptide SEKDEL to the C-terminus. To construct calnexin-S1-10 fusion plasmids 
(CNX-S1-10), cellular RNA was extracted from RK-13 cells using TRIzol (Life 
Technologies). The extracted RNA was reverse transcribed and PCR amplified with 
SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity kit 
(Invitrogen). The template sequences for PDI-S11 and tapasin-S11 constructs were 
acquired using the same method except that HeLa cells were used for the tapasin 
sequence. The N-terminal tags of CNX-S1-10(N), PDI-S11(N) and tapasin-S11(N) 





Table 3.1 List of GFP S11 tagged constructs tested for membrane topology 
 
Name of Construct Promoter GFP S11 Tag 
Location 
Protein Origin 
PDI-S11 (N) VACV E/La N-terminus Cellular 
Tapasin-S11 (N) VACV E/L, CMVb N-terminus Cellular 
Tapasin-S11 (C) VACV E/L, CMV C-terminus Cellular 
L2-S11 (N) Naturalc N-terminus Viral 
L2-S11 (C) Natural C-terminus Viral 
A30.5-S11 (N) Natural N-terminus Viral 
A30.5-S11 (C) Natural C-terminus Viral 
a Vaccinia virus synthetic early/late promoter 
b Human cytomegalovirus (CMV) immediate-early promoter 






S11 fused viral gene constructs (L2-S11(N), L2-S11(C), A30.5-S11(N), and 
A30.5-S11(C)) were made using genomic DNA of VACV WR strain as template for 
PCR amplification with primers containing S11 sequences. The natural promoter of 
each gene was added upstream of the ORF. 
The CMV promoter driven constructs were made by inserting tapasin-S11(N), 
tapasin-S11(C), Cyto-S1-10, ER-S1-10 ORFs and CNX-S1-10(N) and CNX-S1-10(C) 
into pcDNA3.1D/V5-His-TOPO (Invitrogen) vector through directional cloning. 
3.3.4 Confocal microscopy 
RK-13 cells were grown on coverslips in 24-well plates. The cells were 
infected with 3 PFU/cell of VACV strain WR and transfected one hour later with 
split-GFP plasmids using Lipofectamine 2000 (Invitrogen) or with empty vector 
plasmids. The tranfection medium was replaced by fresh medium after 6 h. At 16 h 
post-transfection, the cells were washed with phosphate-buffered saline (PBS) and 
fixed with 4% paraformaldehyde for 15 min at room temperature (RT). A similar 
procedure was used for transfection of plasmids with CMV promoters except that the 
uninfected cells were fixed at 24 h. The fixed cells were permeabilized with 0.1% 
Triton X-100 for 15 min and then blocked with 10% FBS for at least 30 min at RT. 
Primary antibodies were added at a 1:200 dilution in PBS containing 10% FBS for 
overnight at 4°C. The cells were washed and treated with fluorescent dye-labeled 
secondary antibodies (Alexa Fluor, Molecular Probes) at 1:200 dilution for 1 h at RT. 
Finally, the cells were stained with 300 nM DAPI (4’,6-diamidino-2-phenylindole, 




with ProLong Gold Antifade Reagent (Molecular Probes). Confocal images were 
taken using Leica TCS SP5 microscope and processed with Imaris X64 7.6.1 software 
including calculation of Pearson’s colocalization coefficient. Fluorescence 
quantification was also done using Imaris X64 7.6.1 by calculating the signal from 
2,000 to 17,000 cells contained within 50 microscope fields in each sample. The 
number of cells was kept consistent between the samples that were directly compared 
to one another. Background from infected cells transfected with empty vector 
plasmids was subtracted. 
 
3.3.5 Western blotting 
Proteins from infected/transfected cells were resolved by electrophoresis on 4 
to 12% NuPAGE Bis-Tris gels followed by transfer to a nitrocellulose membrane 
using the iBlot system (Life Technologies). Membranes were blocked with 5% nonfat 
milk in PBS containing 0.05% Tween 20 (PBST) for 30 min. Blocked membranes 
were incubated with the primary antibody for 1 h at RT, and then were washed four 
times with PBST. Secondary antibody conjugated with IRDye 800CW (Li-Cor 
Biosciences) was incubated with the membrane (1:5000) for 1 h at RT, followed by 
four washes with PBST. The membranes were then developed using a Li-Cor 






Figure 3.2 Structure and expression of GFP S1-10 proteins 
(A) Diagrams of S1-10 without (Cyto-S1-10) or with signal peptide and ER retention 
sequence (ER-1-10) and S1-10 fused near the N-terminus of calnexin following the signal 
peptide (CNX-S1-10(N)) and S1-10 fused to the C-terminus of calnexin (CNX-S1-10(C)). In 
each case transcription was regulated by the VACV synthetic early/late promoter. (B) RK-13 
cells were infected with VACV and transfected one hour later with the expression plasmids 
diagrammed in panel A. At 4, 8 and 16 h after infection, the cells were lysed and the proteins 
were resolved by SDS-polyacrylamide gel electrophoresis and detected by probing western 
blots with antibody to GFP and actin. ER-S1-10 presumably migrates as a doublet because of 





Figure 3.3 Intracellular localization of GFP S1-10 proteins  
(A) Confocal microscopy of cells transfected with S1-10 expression constructs. Infections 
and transfections were carried out as in Figure 1B. At 16 h the cells were fixed and stained 
with anti-GFP rabbit PAb followed by secondary staining with Alexa Fluor 488 (green). The 
ER luminal protein PDI was stained with anti-PDI mouse MAb and Alexa Fluor 594 (red). 
DNA in nuclei and cytoplasmic virus factories were stained with DAPI (blue). Overlaps of 
S1-10 and PDI signals are shown as yellow in the merged images. (B) Pearson’s 
colocalization coefficient values between S1-10 and PDI signals. A value closer to 1 indicates 





3.4.1 Construction of sensors 
The schematic in Figure 3.1A illustrates the occurrence of fluorescence when 
the S11 and S1-10 GFP fragments interact. Sensors to detect fusion proteins with S11 
tags were constructed by expressing S1-10 as a soluble cytoplasmic protein (Cyto-S1-
10) or an ER luminal protein (ER-S1-10) (Figure 3.1B) or by fusing S1-10 to the N- 
or C-termini of the transmembrane protein calnexin to produce CNX-S1-10(N) and 
CNX-S1-10(C), respectively (Figure 3.1C). The structural features of the four sensors 
are depicted in Figure 3.2A. Cyto-S1-10 is synthesized in the cytoplasm as a free 
protein, whereas ER-S1-10 is fused to an N-terminal signal peptide and a C-terminal 
ER retention sequence so that it resides within the ER lumen. The topology of 
calnexin dictates that the S1-10 fragment of GFP should be in the ER lumen when 
fused to the N-terminus and in the cytoplasm when fused to the C-terminus. 
Transfection experiments indicated that the split-GFP system could be used in 
mammalian cells with CMV promoters or in conjunction with a VACV expression 
system (251). Using the latter system, the proteins were detected by Western blotting 
within 4 h and increased over a 16 h period (Figure 3.2B). The Cyto-S1-10 and ER-
S1-10 proteins localized to cytoplasmic and ER compartments as shown by confocal 
microscopy (Figure 3.3A, B). Both the CNX-S1-10(N) and the CNX-S1-10(C) were 
associated with the ER (Figure 3.3A, B). Thus, GFP S1-10 did not perturb the 







Figure 3.4 Validation of split-GFP method with cellular proteins of known ER membrane 
topology 
(A) RK-13 cells were infected with VACV and one hour later were co-transfected with 
plasmids expressing PDI-S11(N) or tapasin–S11(N) or tapasin-S11(C) together with either 
Cyto-S1-10 or ER-S1-10.  At 16 h after transfection, the cells were fixed and stained with 
DAPI to visualize DNA in nuclei and cytoplasmic virus factories. Fluorescence was analyzed 
by confocal microscopy. Blue, DAPI; green, GFP. (B) Same as panel A except that CNX-S1-
10(N) or CNX-S1-10(C) was used instead of Cyto-S1-10 or ER-S1-10. (C) Diagram showing 




3.4.2 Validation of the system with cellular proteins of known topology 
To further validate the system, we fused S11 to the N-terminus of the luminal 
protein disulfide isomerase (PDI) (252), and to the N- and C-termini of tapasin, a type 
I membrane protein with N-terminal ER luminal and C-terminal cytoplasmic domains 
(253) (Table 1).  Since previous studies had shown that tapasin was functional even 
after fusion of full-length GFP to the N- or C-termini (253, 254), we anticipated no 
difficulties with the short S11 fragment. DNA encoding a PDI or tapasin S11 fusion 
protein was co-transfected with either Cyto-S1-10 or ER-S1-10. A fluorescence 
signal was obtained when PDI-S11(N) was transfected with ER-S1-10 but not with 
Cyto-S1-10 (Figure 3.4A). A signal was obtained when tapasin-S11(N) was 
expressed with ER-S1-10 and when tapasin-S11(C) was expressed with Cyto-S1-10 
but not the converse (Figure 3.4A). Quantification of the fluorescence is shown in 
Figure 3.5. 
Corresponding results were obtained using CNX S1-10 constructs as sensors 
(Figure 3.4B; Figure 3.5). PDI-S11(N) was detected with CNX-S1-10(N) but not 
CNX-S1-10(C), whereas tapasin-S11(N) and tapasin-S11(C) were detected with 
CNX-S1-10(N) and CNX-S1-10(C), respectively. Thus, the topology of PDI and 
tapasin deduced by the split GFP method was consistent with the known topology of 
these proteins (Figure 3.4C). 
The above data were obtained using the VACV expression system. The same 
results were obtained when tapasin-S11 and sensor constructs were expressed using 
CMV promoters in uninfected cells (Figure 3.6), although the expression levels at 24 





Figure 3.5 Quantification of GFP signal of cellular proteins. 
(A-F) Quantification of GFP signal from each combination of S1-10 and S11 construct 
expressed in arbitrary units (a.u.). The fluorescence was quantified from 6,000 to 10,000 cells 
for each combination. The bars indicate the standard deviation of the mean determined from 




























































































































Figure 3.6 Determination of tapasin topology with split-GFP using the CMV promoter 
system. 
(A) RK-13 cells were co-transfected with plasmids expressing tapasin-S11(N) or tapasin-
S11(C) together with either Cyto-S1-10 or ER-S1-10, all expressed by the CMV promoter. At 
24 h after transfection, the cells were fixed and stained as described in Figure 4A. (B) The 
procedures used were the same as in panel A except that the sensors were CNX-S1-10(N) and 




3.4.3 Application of the system to investigate viral proteins of unknown topology 
Having validated their use with cellular proteins of known topology, the split-
GFP method was applied to VACV proteins of undetermined topology. The small L2 
and A30.5 proteins, previously shown to associate independently with the ER and 
with each other, are crucial for formation of viral membrane structures (8, 11). L2 
was predicted to have two transmembrane domains near the C-terminus and a 
hydrophilic N-terminus in the cytoplasm (210). For the present study, L2 was tagged 
with S11 at the N- or C-terminus (Table 1) and co-transfected with S1-10 sensors to 
determine topology. Complementation of L2-S11(N) occurred with Cyto-S1-10 but 
not with ER-S1-10 (Figure 3.7A; Figure 3.8A). In contrast, complementation of L2-
S11(C) occurred with ER-S1-10 but not with Cyto-S1-10 (Figure 3.7A; Figure 3.8B). 
Corresponding results were obtained with the CNX-S1-10(N) and CNX-S1-10(C) 
(Figure 3.7B; Figure 3.8C, D) indicating that the N-terminus of L2 is in the cytoplasm 
and the C-terminus is in the ER lumen (Figure 3.7C).  
The A30.5 protein was predicted to have a central transmembrane domain of 
only 18 amino acids (8). Both A30.5-S11(N) and A30.5-S11(C) (Table 1) were 
complemented by Cyto-S1-10 but not by ER-S1-10 (Figure 3.7D; Figure 3.8E, F). 
Consistent results were obtained with CNX-S1-10(N) and CNX-S1-10(C) (Figure 
3.7E; Figure 3.8G, H) indicating that the N- and C-termini of A30.5 are both 
cytoplasmic. Since the hydrophobic domain is too short to pass through the ER twice, 







Figure 3.7 Determination of the ER membrane topology of viral proteins L2 and A30.5.  
(A) The experiment was carried out as described in Figure 4A a except that plasmids 
expressing L2-S11(N) and L2-S11(C) were co-transfected with plasmids expressing Cyto-S1-
10 or ER-S1-10. (B) Same as panel A except that plasmids expressing CNX-S1-10(N) or 
CNX-S1-10(C) were used as sensors. (C) Diagram showing ER membrane topology of L2 
deduced from GFP complementation. (D) Same as panel A except that A30.5-S11(N) and 
A30.5-S11(C) replaced the L2 constructs. (E) Same as panel D except that CNX-S1-10(N) 
and CNX-S1-10(C) were used as sensors. (F) Diagram of ER membrane topology of A30.5 





Figure 3.8 Quantification of GFP signal of viral proteins. 
(A-H) Fluorescence quantified in arbitrary units (a.u.) from each set of transfections. The 
fluorescence was quantified from 2,000 to 17,000 cells for each combination. The bars 






The asymmetric self-assembling split GFP system offers advantages for quickly 
determining the topology of intracellular proteins: the S11 tag is similar in length to 
commonly used epitope tags and therefore should minimally perturb target proteins; 
multiple options are available for detecting fluorescence in live or fixed cells; 
transfection protocols are adaptable to numerous expression systems and can enable 
high throughput applications. Here I described application of the split GFP system for 
investigating the topology of ER proteins. Variations of the system employing the 
soluble cytoplasmic sensor together with additional sensors can likely be used to 
probe the topology of proteins associated with other cellular organelles such as the 




Chapter 4: Vaccinia virus protein I2 is required for a critical 





The I2L open reading frame of VACV is predicted to encode a conserved 72-
amino acid protein with a C-terminal trans-membrane domain. Previous studies with 
a tetracycline-inducible mutant demonstrated that I2-deficient virions are blocked at 
the entry step of infection. The present study was motivated by a desire to understand 
the step in entry that is enabled by the I2 protein. Our starting point was generation of 
a cell line that constitutively expressed I2 and allowed the construction of the VACV 
I2L deletion mutant vΔI2. As anticipated, vΔI2 was unable to replicate in cells that 
did not express I2. Surprisingly, however, morphogenesis was interrupted after the 
stage of immature virion formation; dense spherical particles accumulated instead of 
brick-shaped mature virions with well-defined core structures. The abnormal particles 
retained the D13 scaffold protein of immature virions, were severely deficient in the 
transmembrane proteins that comprise the entry fusion complex (EFC), and had 
increased amounts of unprocessed membrane and core proteins. A diminished level of 
EFC proteins was also found when the cytoplasmic fraction of cells infected with 
vΔI2, which was attributed to instability due to the hydrophobicity of the EFC 
                                                
2 Some of the data from this chapter are included in a manuscript in preparation for submission (S.I. 




proteins and their failure to be inserted into viral membranes. A similar instability of 
EFC proteins had previously been found with unrelated mutants that also failed to 
form mature virions and accumulated viral membranes retaining the D13 scaffold. 
We concluded that I2 is required for virion morphogenesis although an additional role 
in chaperoning EFC proteins was not excluded. 
 
4.2 Introduction 
Poxviruses are large, double-stranded DNA viruses that replicate entirely in 
the cytoplasm of infected cells (1). Morphogenesis begins with the formation of 
crescent membranes that enlarge to form spherical IVs, which are then transformed 
into brick-shaped MVs (255). Studies with VACV, the prototype member of the 
poxvirus family, indicate that the 60 - 80 viral proteins are associated with the core 
and membrane fractions of MVs (256-259). These proteins enable virus attachment to 
the cell, fusion of viral and cellular membranes, and early gene expression. The EFC 
comprises 11 small trans-membrane (TM) proteins of the MV that are each required 
for the membrane fusion step of virus entry (55, 65). Recently, an additional protein 
encoded by the I2L ORF of VACV, with homologs in all chordopoxviruses, was 
reported to be essential for virus entry, raising the possibility that it represents an 
additional component of the EFC (260). The I2 protein is predicted to have 72 amino 
acids with a calculated mass of 8.4 kDa and a C-terminal TM domain. The protein is 
synthesized following viral DNA replication and is associated with purified MVs 
(260). Using a recombinant VACV with a tetracycline-inducible I2L ORF, Nichols 




virus infectivity due to an inability of the virus to enter cells. Under these conditions, 
they noted a reduction in several EFC components in the viral membrane but 
considered this unlikely to account for the large decrease in the specific infectivity of 
I2-deficient virions, although this possibility was not entirely discounted. 
The purpose of the present study was to further analyze the role of the I2 
protein in VACV replication. Our starting point was to produce an I2L deletion 
mutant with the aid of a complementing cell line. We found that the null mutant has a 
primary block in virion assembly, which was not recognized in previous studies with 
an inducible mutant, and that the decrease in the level of EFC proteins is likely due to 
their instability caused by an inability to associate with viral membranes. 
 
4.3 Materials and Methods 
4.3.1 Cells and viruses 
RK-13, RK-HA-I2, 293T, and BS-C-1 cells were grown in Dulbecco’s 
minimum essential medium (DMEM) or in minimum essential medium with Earle’s 
balanced salt (EMEM) containing 10% fetal bovine serum (Sigma-Aldrich, St. Louis, 
MO), 2 mM L-glutamine, 100 units of penicillin and 100 µg of streptomycin per ml 
(Quality Biologicals, Gaithersburg, MD). For RK-HA-I2 cells, 2 µg/ml of puromycin 
was included as a selection antibiotic. The VACV Western Reserve (vWR) strain was 
propagated as previously described (261). The VACV I2L deletion mutant vΔI2 was 





4.3.2 Construction of RK-HA-I2 cell line 
RK-HA-I2 cells were created using lentiviral transduction (Figure 4.1A). 
Eukaryotic codon-optimized I2L ORF with N-terminal HA tag (HA-I2) was cloned 
into pENTR-D-TOPO (Invitrogen, Carlsbad, CA) to generate pENTR-HA-I2. LR 
Clonase II (Invitrogen) was used to transfer HA-I2 from pENTR-HA-I2 into pLX302, 
yielding pLX302-HA-I2. Lentivirus particles were produced by co-transfecting 
pLX302-HA-I2 (transfer vector), psPAX2 (packaging vector), and pMD2.G (VSV-G 
envelope vector) into 293T cells using Lipofectamine 2000 (Invitrogen). psPAX2 
(Addgene plasmid # 12260) and pMD2.G (Addgene plasmid # 12259) were gifts 
from Didier Trono, and pLX302 (Addgene plasmid # 25896) was a gift from David 
Root (262). RK-13 cells were infected with the harvested lentiviruses, passaged 
several times under selection of 2 µg/ml puromycin selection. Puromycin resistant 
cells were harvested and diluted down to single cell per well in 96-well plates for 
clonal selection. Clones were tested for HA-I2 expression by western blotting using 
anti-HA monoclonal antibody (data not shown), and the best expressing clone was 






Figure 4.1 Construction and selection of RK-HA-I2 cell line 
(A) Diagram of lentiviral transduction method used for making RK-HA-I2 cell line. Western 
blot analysis (B) and immunofluorescence labeling (C) were used to confirm the expression 




4.3.3 Homologous recombination of vΔI2 
 DNA containing the VACV P11 promoter regulated GFP ORF was inserted 
between I2L ORF flanking sequences of approximately 500 bp on each side (Figure 
4.2A), using In-Fusion HD Cloning Kit (Clontech, Mountain View, CA). RK-13 cells 
were infected with 1 PFU/cell of vWR, and transfected with the assembled DNA at 1 
hour post-infection (hpi) using Lipofectamine 2000 (Invitrogen). At 24 hpi, the 
infected/transfected cells were collected and lysed with rapid freeze-thawing cycles 
and sonication. 10-fold serial dilutions of the lysate were incubated with RK-HA-I2 
cell monolayers, and plaques with green fluorescence were picked. Plaque 
purification was repeated five times. Downstream forward primer 5’-
CCGCGGCTAGTCCTATGTTGTATCAACTTC-3’ and upstream reverse primer 5’- 
ATGATATGTATGTCCATTAAAGTTAAATTGTGTAGCGCTTCT-3’ were used 
for PCR and sequencing to verify the deletion of the I2L ORF. 
 
4.3.4 Construction of vGFP-I2 
DNA containing the I2L ORF with N-terminal full-length GFP fusion (GFP-
I2) was assembled with ~500 bp of I2L ORF flanking sequences (Figure 4.10A) into 
a plasmid using In-Fusion HD Cloning Kit (Clontech). Natural promoter of I2 was 
kept in place to regulate GFP-I2. RK-13 cells were infected with vWR and 
transfected with the assembled DNA for homologous recombination as described 
above. vGFP-I2 plaques were picked and purified as previously described, and were 





4.3.5 I2 compensatory mutant generation 
RK-13 cells were infected with 0.1 PFU/cell of vΔI2 in multiple wells of 6-
well plates. After 48 to 72 h, one tenth of the infected cell lysate was passed to new 
sets of cells. This procedure was repeated for 5 to 10 passages until several wells 
started showing signs of viral spread. The wells containing I2 compensatory mutants 
were serially diluted in ten-fold increments and plaques were picked. Selected 
compensatory mutants were analyzed by plaque assay and one-step growth curve. 
The absence of I2L ORF in the compensatory mutants was verified by PCR and 
whole genome sequencing. HindIII restriction enzyme analysis on the genome of the 
compensatory mutants was done as described in a previous report (50). 
 
4.3.6 Antibodies 
The mouse MAb against human influenza virus hemagglutinin (HA) was from 
Covance (Cat. MMS-101P, Princeton, NJ). Mouse anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) MAb was from Santa Cruz Biotechnology (Cat. sc-32233, 
Dallas, TX), and rabbit anti-actin polyclonal antibody (PAb) was from Sigma-Aldrich 
(Cat. A2066). PAbs used for VACV protein detection were rabbit antisera to A3 
(unpublished data), A10 (unpublished data), A11 (206), A17-N (230), A21 (66), A27 
(60), A28 (263), D13 (226), F9 (68), F10 (264), G3 (78), G7 (265), H2 (74), H3 
(266), I7 (267), L1 (268), L5 (67), and to WR strain (269). Mouse MAbs used against 
VACV proteins were to A14 (270) and D8 (271). PAb against GFP was from 




and calnexin (sc-6465) were from Santa Cruz Biotechnology, and Alexa Fluor 
secondary antibodies were from Molecular Probes (Eugene, OR). 
 
4.3.7 Purification of viral particles 
Virions of vWR and vΔI2 were first sedimented through a 36% sucrose 
cushion as previously described (261), then banded on a cesium chloride (CsCl) 
gradient (258, 272, 273). The gradient was formed by prelayering 1.3 g/ml (bottom, 
3.5 ml), 1.25 g/ml (middle, 4 ml), 1.2 g/ml (top, 3.5 ml) CsCl solutions and allowing 
it to diffuse overnight at 4°C on a stable surface. CsCL solutions were made in 10 
mM Tris-HCl calculations from (274). Sedimented virus material from the sucrose 
cushion was layered over the CsCl gradient and centrifuged for 4 h at 180,000 x g in a 
TH-641 rotor. Banded virions were extracted from the gradient and diluted 3-fold 
with 1 mM Tris-Cl. Virions were then repellected and collected by additional 
centrifugation. 
 
4.3.8 Plaque assay and virus yield determination 
BS-C-1, RK-13, or RK-HA-I2 cell monolayers were used for plaque assays in 
6-well plates. Virus samples were serially diluted in 10-fold increments and incubated 
with the monolayers at 37°C. After 1 h, the medium was aspirated and replaced by 
medium containing 0.5% methylcellulose. At 48 hpi, the cells were stained with 




plaque counting. Counted plaques from each well were used to calculate virus yields 
based on their respective dilution factors. 
 
4.3.9 Droplet digital PCR 
RK-13 cells were infected with 10 PFU/cell of either vWR or vΔI2. At 10 hpi, 
mRNA was extracted from infected cells using Trizol LS (Invitrogen). Extracted 
mRNA was reverse transcribed to cDNA with SuperScript VILO MasterMix 
(Invitrogen). The cDNA was serially diluted and used as a template for droplet digital 
PCR (Bio-Rad, Hercules, CA). Following the manufacturer’s protocol, the digital 
PCR was carried out for multiple viral transcripts with primers internally binding 
each ORF. The primers were designed using PrimerQuest Tool from Integrated DNA 
Technologies (Coralville, IA)(Table 4.1). After 40 cycles of reaction, the droplets 
were digitally analyzed with the droplet reader (Bio-Rad) and absolute mRNA copy 
numbers were obtained. 
 
4.3.10 Radioactive pulse-labeling and chase 
RK-13 cells were infected with 5 PFU/cell of vWR or vΔI2 at 37°C. After 5.5 
h, the infected cells were incubated with medium lacking methionine and cysteine for 
30 min at 37°C. 2.5% dialyzed FBS was used in methionine/cysteine-free medium. At 
6 hpi, the cells were pulse-labeled at 37°C for 5 min with 100 µCi of [35S]-
methionine/cysteine (Perkin-Elmer, Waltham, MA). Following the pulse, medium 




chase. At various chase time points, the cells were washed with cold phosphate-
buffered saline (PBS) and lysed with 1% NP-40 containing complete protease 
inhibitor cocktail (Roche Applied Science, Indianapolis, IN). The lysates were 
clarified by centrifugation and proteins were immunoprecipitated using Protein G 
Dynabeads (Life Technologies, Carlsbad, CA). The radiolabeled proteins were 
resolved in a 4 to 12% polyacrylamide gel, which subsequently was fixed in 40% 
methanol/10% acetic acid, soaked in 10% glycerol, dried, and exposed to a phosphor 
screen. Typhoon Variable Mode Imager (GE Healthcare, Chicago, IL) was used to 
detect radioactive bands from the phosphor screen. 
 
4.3.11 Confocal microscopy 
RK-13 cells were grown on coverslips in 24-well plates, and were infected 
with 3 PFU/cell of vGFP-I2. At 8 hpi, the cells were washed with PBS and fixed with 
4% paraformaldehyde for 15 min at room temperature (RT). The fixed cells were 
permeabilized with 0.1% Triton X-100 for 15 min and then blocked with 10% FBS 
for at least 30 min at RT. Primary antibodies were added at a 1:200 dilution in PBS 
containing 10% FBS for overnight at 4°C. The cells were washed and treated with 
fluorescent dye-labeled secondary antibodies (Alexa Fluor, Molecular Probes) at 
1:200 dilution for 1 h at RT. Subsequently, the cells were stained with 300 nM DAPI 
(4’,6-diamidino-2-phenylindole, Molecular Probes). The coverslips were then 
mounted on a glass microscope slide with ProLong Gold Antifade Reagent 
(Molecular Probes). Confocal images were taken using Leica TCS SP5 microscope 




Table 4.1 List of primers used for droplet digital PCR 














































4.3.12 Transmission electron microscopy 
Infected RK-13 or RK-HA-I2 cells in 60-mm plates were fixed with 2% 
glutaraldehyde in 0.1 M sodium cacodylate buffer, postfixed in 1% reduced osmium 
tetroxide, dehydrated in a series of ethanol incubations with final dehydrations in 
propylene oxide, and embedded in EmBed-812 resin (Electron Microscopy Sciences, 
Hatfield, PA)(210). Procedures for cryosectioning and immunogold labeling were 
described previously (275). Cryosections were picked up on grids, thawed, washed 
free of sucrose, and stained with rabbit polyclonal D13 antibody, and then protein-A-
conjugated to 10-nm gold spheres (University Medical Center, Utrecht, Netherlands). 
Specimens were viewed with an FEI Tecnai Spirit transmission electron microscope 
(FEI, Hillsboro, OR). 
 
4.3.13 Western blotting and signal quantification 
Proteins from cells or purified virions were prepared with NuPAGE (Life 
Technologies) lithium dodecyl sulfate buffer and reducing agent, resolved by 
electrophoresis on 4 to 12% NuPAGE Bis-Tris gels, and transferred to nitrocellulose 
membranes using the iBlot system (Life Technologies). Membranes were blocked 
with 5% nonfat milk in Tris-buffered saline (TBS) containing 0.05% Tween 20 
(TBST) or with Odyssey Blocking Buffer (Li-Cor Biosciences, Lincoln, NE) for 30 
min to 1 h. Blocked membranes were incubated with the primary antibody for 1 h at 
RT or for overnight at 4°C, and washed four times with TBST. Secondary antibody 
conjugated with IRDye 800CW or 680RD (Li-Cor Biosciences) was incubated with 




membranes were scanned using Li-Cor Odyssey infrared imager, and band signal 
intensities were acquired with Image Studio software (Li-Cor Biosciences). 
 
4.3.14 Whole genome sequencing 
Approximately 2 x 107 infected RK-13 cells were Dounce homogenized and 
sedimented through a 36% sucrose cushion as previously described (261). The pellet 
was resuspended in 200 µl of PBS, and DNA was extracted using Qiagen DNA Blood 
Kit (Qiagen, Hilden, Germany). Extracted DNA samples were processed into paired-
end libraries with the Illumina TruSeq DNA (Illumina, San Diego, CA) protocol. The 
libraries were sequenced on the HiSeq 2000 next-generation sequencer (Illumina), 
generating reads of ~100 bp in length. The reads were mapped to VACV genome and 
analyzed using Integrative Genomics Viewer (Broad Institute, Cambridge, MA) or 
Geneious software (Biomatters, Auckland, New Zealand). 
 
4.3.15 Chemical cross-linking and immunoprecipitation 
RK-13 cells were infected with vWR or vGFP-I2 at 3 PFU/cell. At 8 or 16 hpi, 
one half of the samples were chemically cross-linked using 1% paraformaldehyde for 
30 min at RT and quenched for 15 min with 5 mM glycine. Crosslinked and non-
crosslinked cells were lysed with immunoprecipitation (IP) buffer composed of: 1% 
NP-40, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, and complete 
protease inhibitor cocktail (Roche Applied Science). The lysates were clarified by 





Figure 4.2 Construction of the I2L deletion mutant 
(A) Diagram of vΔI2 construction design showing flanking genes of I2, which is replaced by 
P11 promoter-regulated GFP. (B) Plaque phenotypes of vΔI2 and wild-type vaccinia virus 
WR strain (vWR). RK-HA-I2, RK-13, and BS-C-1 cells were infected at multiplicity of 
0.0007 PFU/cell of vΔI2 or vWR. At 48 hpi, the infected cells were washed and stained with 
crystal violet. (C) Enlarged fluorescent plaque images. RK-13 and RK-HA-I2 cells were 
infected as in panel B. At 48 hpi, the cells were imaged under fluorescence microscope. 
White arrows indicate cells infected with vΔI2, which failed spreading to neighboring cells. 
(D) One-step growth curves of vΔI2. RK-HA-I2 and RK-13 cells were infected with 3 
PFU/cell of vΔI2. The infected cells were collected at 0, 4, 8, 12, 24, and 48 hpi. Virus titers 
for each time points were determined by plaque assay using RK-HA-I2 cells. The experiment 




magnetic beads (Chromotek, Martinsried, Germany). GFP-I2 was bound with anti-




4.4.1 Construction of an I2L deletion mutant 
Because repression of gene expression by inducible mutants can be 
incomplete, we decided to construct an I2L deletion mutant. However, since I2 is 
essential for replication, it was first necessary to make a cell line that expresses I2 and 
can complement a virus null mutant. We chose rabbit kidney RK-13 cells because 
they are permissive for VACV and have previously been used to make 
complementing cell lines that express other VACV genes (276, 277). A eukaryotic 
codon-optimized version of the I2 ORF with a N-terminal HA tag was incorporated 
into a lentiviral vector, which was then used for gene delivery to RK-13 cells (Figure 
4.1A). Transduced cells were isolated by antibiotic selection and clonally purified. 
Western blotting (Figure 4.1B) and fluorescence microscopy demonstrated expression 
of HA-I2 by the RK-HA-I2 cells (Figure 4.1C). 
To delete the I2L ORF of VACV, DNA encoding GFP regulated by the 
VACV late P11 promoter was flanked by sequences upstream and downstream of I2L 
(Figure 4.2A) and transfected into RK-13 cells that were infected by VACV to allow 
homologous recombination.  The mutant viruses formed green fluorescent plaques on 




I2L ORF was confirmed by sequencing. As expected, vΔI2 was unable to form large 
plaques in the parental RK-13 cells or in BS-C-1 cells (Figure 4.2B). At high 
magnification, single RK-13 cells infected with vΔI2 could be detected by their 
fluorescence but spread to neighboring cells did not occur (Figure 4.2C). 
Furthermore, vΔI2 replicated to high titer in RK-HA-I2 cells but not in RK-13 cells 
(Figure 4.2D) 
 
4.4.2 Replication of vΔI2 blocked during morphogenesis 
RK-13 and RK-HA-I2 cells were infected with vΔI2 and examined by 
transmission electron microcopy in order to determine the stage at which virus 
replication was inhibited. We discovered that morphogenesis was grossly disrupted in 
non-complementing RK-13 and BS-C-1 cells. The cytoplasm contained large, 
granular, bodies with crescent membranes on their periphery and relatively normal 
looking IVs but MVs were not found (Figure 4.3A, B, E, and F). Instead of MVs, 
there were dense spherical virions (or incomplete MVs). These images contrasted 
with the overall normal appearance of IV, MVs and wrapped MVs in RK-HA-I2 cells 
infected with vΔI2 (Figure 4.3C and D) and with similar structures in RK-13 and RK-
HA-I2 cells infected with the parental wild type VACV (not shown). 
The transformation of spherical IVs to brick-shaped MVs is accompanied by 
disassembly of the external scaffold formed by trimers of the D13 protein (219, 220). 
The latter step is accompanied by the processing of the A17 membrane protein that is 
associated with the D13 trimers (221, 222). Antibody to the D13 protein and protein 









Figure 4.3 Transmission electron micrographs of cells infected with vΔI2 
RK-13 cells (A, B), RK-HA-I2 cells (C, D), and BS-C-1 cells (E, F) were infected with 3 
PFU/cell of vΔI2. At 18 hpi, the cells were harvested, fixed, and prepared for transmission 
electron microscopy. C: crescent, D: dense virion, IV: immature virion, InMV: incomplete 
mature virion, MV: mature virion, WV: wrapped virion, EV: enveloped virion. Scale bars are 







Figure 4.4 Immuno-electron microscopy images showing localization of D13 in IVs and 
dense virions 
RK-13 cells (A, B) and RK-HA-I2 cells (C, D) were infected with 3 PFU/cell of vΔI2. Cells 
were collected at 18 hpi for fixation and preparation for immuno-electron microscopy using 
primary polyclonal antibody to D13. IV: immature virion, nu: nucleoid, MV: mature virion. 





RK-HA-I2 cells infected with vΔI2. D13 was associated with the IVs and the dense 
spherical particles in in RK-13 cells (Figure 4.4A and B). In RK-HA-I2 cells, D13 
was also associated with IVs but not MVs (Figure 4.4C and D). Thus, I2 deficiency 
prevented the removal of the D13 scaffold and further steps of morphogenesis. The 
accumulation of dense spherical particles retaining D13 was previously noted when 
the synthesis of the I7 protease was repressed (221). 
 
4.4.3 I2-deficient virus particles have low levels of EFC proteins 
Nichols and co-workers (260) previously compared the proteins associated 
with I2–deficient virus particles made in the absence of tetracycline inducer and wild 
type virus particles by western blotting. They found normal amounts of most proteins 
but an approximate 5-fold decrease in A21, G3 and A28, which are each components 
of the EFC. We carried out a similar comparison of vΔI2 and wild type virus particles 
assembled in RK-13 cells. Specific antibodies were used to analyze 15 proteins of 
which seven were components of the EFC, seven were other membrane and core 
proteins and one was the D13 scaffold protein. There was on average a 10-fold 
reduction in the amount of each EFC protein in the I2-deficient virus particles 
compared to the amounts in wild type virus particles (Figure 4.5A). In contrast, there 
were similar amounts of the other proteins with one striking exception, a 30-fold 
increase in D13 in the I2-deficient virus particles (Figure 4.5B). The retention of D13 
was consistent with the immunogold labeling of the dense spherical particles (Fig, 





Figure 4.5 Proteins in cesium chloride (CsCl) gradient purified virions 
vWR and vΔI2 lanes refer to vWR and vΔI2 virions, respectively. (A) Western blots probing 
for vaccinia virus entry/fusion proteins. (B) Western blots for other vaccinia proteins 
including attachment, core, and morphogenesis proteins. vWR:vΔI2 shows relative band 
intensities of vΔI2 samples compared to vWR samples, which is scaled to 100. D13 is an 





Figure 4.6 Proteins in total infected cell extracts 
Either RK-13 or RK-HA-I2 cells were infected with 3 PFU/cell and lysed at 20 hpi. vWR and 
vΔI2 lanes refer to RK-13 cells infected with vWR and vΔI2, respectively. vΔI2+I2 lanes 
represent RK-HA-I2 cells infected with vΔI2. (A) Overall expression of vaccinia virus 
proteins visualized using anti-WR. Western blots probing vaccinia entry/fusion proteins (B), 
other proteins such as vaccinia attachment, core, morphogenesis, and cellular loading control 




proteins seen as higher bands in the western blots (Figure 4.5B), consistent with a 
perturbation in morphogenesis. 
 
4.4.4 Decreased accumulation of EFC proteins in vΔI2-infected RK-13 cells 
In view of the greatly diminished amounts of the EFC proteins in the purified 
virus particles, we were curious to determine their abundance in infected cells. 
Lysates of RK-13 cells infected with WT VACV or vΔI2 and of RK-HA-I2 cells 
infected with vΔI2 were analyzed by SDS-PAGE and western blotting. The pattern of 
abundant viral proteins appeared indistinguishable when the blot was probed with 
antiserum from rabbits that were infected with VACV (269), indicating the absence 
of a general effect on viral protein synthesis (Figure 4.6A). Nevertheless, there were 
lower amounts of the EFC proteins in RK-13 cells infected with vΔI2 compared to 
vWR (Figure 4.6B). Although there was some variation, the difference was about 4-
fold. This effect was partially overcome when RK-HA-I2 cells were infected with 
vΔI2 (Figure 4.4B). In contrast, the abundance of the non-EFC proteins was very 
similar in the cells infected with vWR and vΔI2, although again we noted greater 
amounts of unprocessed A3 and A17 in cells infected with vΔI2 (Figure 4.6C).  
We also compared the levels of the scaffold protein D13 and I7, the proteinase 
responsible for cleavage of both A3 and A17 and needed for disassembly of D13, in 
RK-13 cells infected with vΔI2. Although D13 was present in similar amounts, I7 
was reduced about 3-fold (Figure 4.6D). As the previous report (184) with the 
repression of I7 expression showed similar defective dense virions in EM (Figure 








Figure 4.7 Inducible and temperature-sensitive mutants of I7  
(A) Transmission electron micrographs of BS-C-1 cells infected for 24 h with vI7Li in the 
absence of IPTG. Arrows on the left panel point to irregularly shaped dense particles, and 
arrows with ‘c’ indicate poorly formed cores. Abbreviations: n, nucleoid; IV, immature 
virion. The micrographs were reprinted from Ansarah-Sobrinho et al. (184) with permission. 
(B) vI7Li (184) was used to infect RK-13 cells at 3 PFU/cell at 37°C with (+) or without (-) 
25 µM isopropyl β-D-1-thiogalactopyranoside (IPTG). At 20 hpi, the cells were lysed and 
analyzed by SDS-PAGE and western blotting. (C) Temperature-sensitive mutant of I7 
(ts16)(267, 278) was used to infect BS-C-1 cells at 5 PFU/cell. After initial incubation at 
31°C for 1 h of virus absorption, the cells were separately incubated in 31 or 40°C for 18 h. 
Then the cells were harvested, lysed, resolved by SDS-PAGE and analyzed by 






did in I2 deletion mutant. However, I7 repression by an inducible or a temperature-
sensitive mutant did not produce a dramatic effect on the EFC protein levels (Figure 
4.7B and C). Regardless, a virus with a complete knockout of the I7L gene would be 
more appropriate for direct comparison. 
Time course expression analysis showed that late protein synthesis was first 
seen around 6 and 8 hpi with vΔI2 and slightly later with vWR (Figure 4.8A). 
Background bands at earlier time points were more visible with vΔI2 than vWR 
(Figure 4.8A) as there are presumably more proteins associated with the virus 
inoculum due to its high particle to PFU ratio suggested by the lower virus titer.  
The low amounts of the EFC proteins could be due to diminished synthesis or 
protein instability. To distinguish between these possibilities we carried out digital 
PCR to determine mRNA levels and pulse-labeling with radioactive amino acids to 
determine protein synthesis and stability. The viral mRNAs encoding EFC and non-
EFC proteins were similar in quantity in RK-13 cells infected with vWR or vΔI2 
suggesting that the difference in protein levels did not have a transcriptional basis 
(Figure 4.8B). We chose to analyze the synthesis and stability of L1 because of the 
availability of a MAb that could be used for immunoaffinity capture (279, 280). 
Likewise, F9 PAb and D8 MAb were also used. After a 5 min labeling period, the 
intensity of the L1 and F9 bands from RK-13 cells infected with vWR and vΔI2 were 
similar suggesting similar rates of translation. However, the vΔI2 bands declined 
more rapidly during a 2 h chase indicating greater instability (Figure 4.8C, D, and E). 










Figure 4.8 Expression of EFC proteins 
(A) Time course expression profile.  RK-13 cells were infected with 10 PFU/cell of vWR and 
vΔI2. M: mock infection. At indicated time points, the cells were lysed and analyzed by SDS-
PAGE and immunoblotting with specific antibodies to individual proteins. (B) mRNA levels. 
RK-13 cells were infected at a multiplicity of 10 PFU/cell with vWR or vΔI2. At 10 hpi, 
RNA was extracted from infected cells and reverse-transcribed to cDNA. Primers for 
indicated genes were used for digital PCR and the number of copies of each mRNA in 2.5 µg 
of total RNA was determined. (C) Pulse-chase. RK-13 cells were infected with 5 PFU/cell of 
vWR or vΔI2. At 6 hpi, the cells were pulse-labeled with 100 µCi of [35S]-methionine-
cysteine for 5 min in methionine-cysteine-deficient medium and then chased in label-free 
normal medium. At the indicated time, lysates were prepared and L1, F9 and D8 proteins 
were immunopurified with specific antibodies and analyzed by SDS polyacrylamide gel 
electrophoresis and autoradiography. Band intensities for L1 (D) and F9 (E) were acquired 





Figure 4.9 MG132 proteasome inhibitor effect on EFC proteins 
RK-13 cells were infected with 10 PFU/cell of vWR, vΔI2 (A), or vKZL106P-S-EGFP (B). 
At 6 hpi, the cells were treated with (+) or without (-) 10 uM MG132 and lysed at indicated 
times. Lysates were resolved by SDS-PAGE and probed for each of the protein shown. PAbs 
and MAbs to individual viral proteins, GFP, and GAPDH were used. vKZL106P-S-EGFP, a 
gift from Jon Yewdell lab, was used as a control as it expresses SCRAP-GFP that has been 






vWR and vΔI2 as expected (Figure 4.8C). A proteasome inhibitor MG132 treatment 
could not stabilize the EFC proteins (Figure 4.9). 
 
4.4.5 Intracellular localization and protein-protein interaction of I2 
To determine intracellular localization of I2, we constructed a recombinant 
VACV expressing N-terminal GFP-tagged I2 called vGFP-I2 (Figure 4.10A). GFP-I2 
replaced the original I2L ORF and natural I2 promoter was used to regulate its 
expression. vGFP-I2 was replication-competent, though slightly less productive than 
wild type (data not shown). Green fluorescence from GFP-I2 was weaker than what 
was observed from P11 promoter regulated GFP (data not shown), suggesting natural 
I2 expression is not as strong. 
 In confocal microscopy, GFP-I2 localized to the viral factory in the 
cytoplasm.  Other viral factory proteins A11 and A14 overlapped with GFP-I2, 
although GFP-I2 signals covered larger area than the other two (Figure 4.10B and C). 
When stained for I7, GFP-I2 signals co-localized well with the I7 signal (Figure 
4.10D). Although I2 has a putative transmembrane domain, I2 only partially 
overlapped with ER marker proteins calnexin and PDI (protein disulfide 
isomerase)(Figure 4.10B and C) suggesting that it did not specifically localize with 
this cellular organelle.  
 Another potential use of vGFP-I2 was to detect proteins that associate with I2 
by immunoprecipitation of the GFP fusion tag. vGFP-I2 infected cells were either 









Figure 4.10 Intracellular localization and immunoprecipitation of GFP-I2 
(A) Diagram of vGFP-I2 construction. GFP-I2L fusion DNA was inserted between the I1L 
and I3L ORFs that flank the original I2L ORF. Natural I2L promoter regulates the 
transcription of GFP-I2L. Arrows indicate the direction of transcription. (B, C, and D) 
Immunofluorescence microscopy of RK-13 cells infected with 3 PFU/cell of vGFP-I2. At 8 
hpi the cells were fixed and stained with mouse MAb to A14, goat PAbs against PDI, 
calnexin, or rabbit PAbs to A11, I7 followed by secondary staining with Alexa Fluor 568 
(red) or 647 (cyan). Nuclear DNA and cytoplasmic viral DNA were stained with 4’,6-
diamidino-2-phenylindole (DAPI, blue). Green fluorescence from GFP-I2 is shown in green. 
Merge shows overlay of all images in each panel. (E and F) RK-13 cells were infected with 
vWR or vGFP-I2 at 3 multiplicity of infection. At 16 hpi, the infected cells were cross-linked 
(+) with 1% paraformaldehyde (one half the samples were not cross-linked, -), lysed and 
incubated with GFP-Trap magnetic beads for immunoprecipitation (IP) of GFP-I2. Following 
the IP, samples were resolved by SDS-PAGE and analyzed by silver staining (E) or by 
western blot using anti-GFP rabbit polyclonal antibody (F). GFP-I2 bands (35 kDa) are 







were used as a negative control. A ladder of multiple bands was seen above and 
below the 35 kDa GFP-I2 band (white asterisks) for both cross-linked and non-cross-
linked samples in total protein staining (Figure 4.10E). Similar trend with fewer 
bands was observed in a western blot analysis using anti-GFP polyclonal antibody 
(Figure 4.10F). However, the input samples in Figure 4.10F also showed nearly 
identical ladder patterns. Therefore, no proteins associated with I2 were detected by 
this method. 
 
4.4.6 Analysis of I2 compensatory mutants 
To screen for the possibility that spontaneous mutations could overcome the 
replication defect due to the absence of I2, we continuously passaged vΔI2 in five 
separate passage lines using RK-13 cells. At as early as the fifth passage, I2 
compensatory mutants were found replicating in non-complementing RK-13 cells 
without I2. Among the five different passage lines, three clones were isolated from 
line number 2 (vcI2-2a, vcI2-2b, and vcI2-2c) and one clone was isolated from line 
number 5 (vcI2-5a). Remaining passage lines, however, did not contain any 
compensatory mutants throughout ten passages. While vΔI2 could not form any 
plaque in the non-complementing cells, the isolated compensatory mutants were able 
to form plaques although they were smaller than those of vWR (Figure 4.11A). The 
vcI2-2a formed smaller plaques than other clones vcI2-2b, vcI2-2c, and vcI2-5a 





In principle, the increased replication of the mutant viruses could be due to 
changes in gene sequences or expression. Previous studies have identified 
duplications and transpositions that resulted in the increase of overall genome sizes 
(48, 282). Elde and co-workers (282) reported that poxviruses rapidly adapted in 
response to changing host responses with gene amplifications. To determine if our 
compensatory mutants have used such modification strategy to overcome the absence 
of I2, we digested the viral genome with the HindIII restriction enzyme. Notably, 
vcI2-2c had two additional fragments (marked with white asterisks) when compared 
to vWR and vΔI2 genomes (Figure 4.11C). If there was simply a duplication, then we 
would not have expected to see all of the original size fragments. One explanation is 
that the duplication was unstable and was continuously being lost.  With the 
exception of vcI2-2a that showed no difference with the parent vΔI2, other clones 
(vcI2-2b and vcI2-5a) also showed the same additional bands in the HindIII 
restriction analysis (data not shown). Fragment close to the 6557 bp sized ladder was 
slightly larger for vΔI2 and vcI2-2c than vWR, as null-I2 mutants contained a larger 
GFP ORF instead of the I2L ORF of vWR within the fragment (Figure 4.11C).  
To further analyze the modifications made in the genomes of I2 compensatory 
mutants, whole genome sequencing was done with the Illumina system. Millions of 
reads of about 100 bp in length were generated and mapped to the VACV genome. As 
expected, both vΔI2 and its compensatory mutants were missing the I2L ORF. The I2 
compensatory mutants merely contained several point mutations and small deletions 
compared to the reference genome in GenBank, but these were also present in the 




were rather identified in the number of reads mapped to certain regions of the 
genome. Peaks were generated across the VACV genome, with the height of the peak 
dependent on the number of mapped reads. While vΔI2 peaks plateaued throughout 
the genome before the inverted terminal repetitions (ITRs), vcI2-2c peaks doubled 
and tripled in height at around the 176,000 and 188,000 nucleotide positions, 
respectively (arrows, Figure 4.11D). With the exception of vcI2-2b, all other I2 
compensatory mutants showed the same duplication/triplication patterns (data not 
shown). Because nucleotide position scale in Figure 4.11D is not entirely accurate 
due to incompletely mapped reads that extended the ends of the genome, the 
duplicated/triplicated regions were extracted separately and re-aligned to the VACV 
genome. As a result, the predicted start position for duplication was found to be 
around 171323, and at around 182233 for triplication. 32 ORFs were encoded within 
the duplicated/triplicated sequences, as listed in Table 4.2. The results of the sequence 







Figure 4.11 Analysis of I2 compensatory mutants 
(A) Plaque assay of RK-13 cells infected with vWR, vΔI2, or with four other I2 
compensatory mutants. Each virus stock was serially diluted and incubated in a 6-well plate 
containing monolayers of the RK-13 cells. After 48 h, the cells were washed and stained with 
crystal violet. (B) One-step growth curve analysis of the four I2 compensatory mutants along 




48 h) and disrupted by repeated freeze-thaw cycles followed by sonication. Ten-fold dilutions 
of the lysates were plated for virus yield determination. The experiment was done three times 
and the mean is plotted with error bars representing the standard deviation. Blue: vWR, 
black: vΔI2, red: vcI2-2a, green: vcI2-2b, magenta: vcI2-2c, orange: vcI2-5a. (C) HindIII 
restriction enzyme analysis of vWR, vΔI2, and vcI2-2c genomes. RK-13 cellular DNA was 
analyzed as a control. The λ-HindIII ladder is shown on the left labeled in base pairs (bp). 
White asterisks indicate additional HindIII fragments of vcI2-2c not present in vΔI2 or vWR 
genome fragments. (D) Peaks showing whole genome sequencing reads of vΔI2 and vcI2-2c 
mapped to VACV genome. The reads are approximately 100 bp in length and the height of 
the blue peaks represents the number of reads assembled to the corresponding region of the 
genome. Nucleotide position of the genome is labeled along the top and the scale on the left 
reflects the number of mapped reads according to the height of the peak. The arrows point to 
increases (bumps) in the number of mapped reads suggesting duplication and triplication of 






Table 4.2 List of ORFs within duplicated/triplicated regions of vaccinia virus I2 
compensatory mutant 
Position in genomea Open reading frame 



























epidermal growth factor-like protein (EGF-like protein)e 
ITR paralog: VACWR009, C11R gene 
hypothetical protein 
ITR paralog: VACWR010, C10L gene 
zinc finger-like; apoptosisf 
ITR paralog: VACWR011 gene 






a Nucleotide position starting from the left end of the genome 





Nichols and co-workers (260) previously reported that the I2L gene encodes a 
membrane protein with an essential role in virion entry. We were interested in 
following up this study in order to determine the stage of entry that was affected and 
therefore decided to construct an I2L deletion mutant for high stringency. Several 
previous studies successfully constructed and propagated VACV mutants with 
deletions of essential genes by making a complementary cell line that expresses the 
missing gene (8, 211, 276, 277). We introduced an HA-tagged I2 gene regulated by a 
eukaryotic promoter into RK-13 cells using a lentivirus vector and screened 
antibiotic-resistant mutants for expression of the HA tag. The cell line isolated stably 
expressed HA-I2 though the level was less than achieved by virus infection. 
Nevertheless, we succeeded in deleting the I2L gene from VACV and propagating the 
mutant in the cell line achieving yields about a log lower than that of wild type virus. 
As anticipated, the virus was unable to replicate in cells not expressing I2, confirming 
the requirement for this gene. We were surprised, however, to discover a block in 
morphogenesis. Although IVs appeared normal, spherical dense particles 
accumulated instead of brick-shaped MVs. Although these particles contained normal 
amounts of most core and membrane proteins, they were greatly deficient in EFC 
proteins, had an increased amount of the D13 scaffold protein, and increased amounts 
of unprocessed A3 and A17 proteins. Thus, failure to disassemble the scaffold 
appeared to be a major defect that was previously reported to occur when I7, the 




repressed (221). Coincidentally, we noted that there was a reduced amount of I7 
detected in cytoplasmic extracts of RK-13 cells infected with vΔI2.  
The EFC proteins have either N- or C-terminal transmembrane domains but 
lack signal peptides and their modes of insertion into the viral membrane have not 
been investigated. However, electron microscopic studies showed that in contrast to 
A17, which is detected in both IVs and MVs, L1 is only detected in MVs suggesting 
that insertion of the EFC proteins may occur after removal of the D13 scaffold (279). 
In the present study, we found that the EFC proteins were also diminished when the 
total cell lysate was analyzed, though not to the same extent as in purified virus 
particles. A specific diminution in EFC proteins was previously noted when the 
formation of IVs was impaired resulting in the absence of MVs due to deletion or 
repression of viral membrane assembly proteins (VMAPs) notably A6, A11, A30.5, 
H7 and L2 (8, 10, 205, 206, 208, 209, 211). A common feature of the I2 deletion 
mutant and the VMAP mutants is the failure to form membranes lacking the D13 
scaffold. We suggest that the EFC proteins are only able to insert into the viral 
membrane after removal of D13 and that they are unstable because of their 
hydrophobicity when prevented from inserting into viral membranes. The two major 
modes of protein degradation in eukaryotic cells are the ubiquitin-proteasome and 
autophagy-lysosomal pathways. We were unable to stabilize the EFC proteins by 
addition of the proteasome inhibitor MG132 and which if either of the canonical 
pathways is involved is uncertain at this time. 
As discussed above, the simplest model to explain the defect in replication of 




or disassembly and that the deficiency of EFC proteins is secondary (Figure 4.12). 
However, it is possible that I2 has multiple functions in association with the 
localization or activation of I7 proteinase or in chaperoning the EFC proteins. The 
study highlights the need to better understand the pathway of insertion of the EFC 
proteins in the viral membrane. Studies on protein interaction and compensatory 
mutants of I2 may provide insights to the stronger understanding of I2. Further 






Figure 4.12 Model for defects caused by the absence of I2 
During a wild type (WT) VACV infection, crescents membranes coated with the D13 
scaffold protein form, enlarge to form spherical immature virions (IVs) containing the DNA 
and core proteins. Further morphogenesis involves processing of the A17 membrane protein 
by I7 proteinase, removal of the D13 scaffold, recruitment of the EFC proteins and a change 
in shape. The IVs also form during infection with the I2 deletion mutant vΔI2, but the D13 
scaffold protein is not removed and the change to the brick-shape with a well-defined core 
does not occur. Under these conditions, the EFC proteins fail to be inserted into the viral 









5.1 Use of Split-GFP for Vaccinia Virus Morphogenesis Studies 
With recent studies reporting evidence of ER membranes as the source of 
poxviral membranes (8, 211), we were highly interested in uncovering the intricate 
mechanism of how the virus makes use of the cellular membrane. There is a vast 
amount of uncertainty in VACV morphogenesis from the start to the end. The recent 
studies merely gave us a starting point, which is the ER membrane. Yet this is 
invaluable information that was greatly missed during the past years of poxvirus 
research. It generated numerous questions related to the use of ER membrane by the 
virus, from how the membrane is sectioned into pieces to how the virus stabilizes the 
breaks. It is not just one or two proteins that are necessary for VACV morphogenesis, 
but already a large number of VACV proteins have been shown to be required for 
morphogenesis (178). Moreover, the involvement of host cell proteins cannot be ruled 
out. At the moment, it seems that great efforts are going to be needed towards the 
complete understanding of morphogenesis, but every step should help to reach the 
goal. 
The split-GFP project was started to reveal the ER membrane topology of 
VACV morphogenesis proteins, and we believe that this step would guide us to more 




determining protein topology (9, 233, 234, 236-238, 283-285), we wanted to develop 
a new method that is quick and versatile. In chapter 3, we were able to determine the 
topology of VMAPs L2 and A30.5, providing useful information when designing 
studies to reveal the function and mechanism of interaction between those proteins. 
Fluorescence signals from the N-terminus of L2 were detected in the cytoplasm and 
those of C-terminus were detected in the ER lumen. For A30.5, both the N- and C-
terminus were shown to be facing the cytoplasm. With this information, we can 
predict that the L2-A30.5 interaction occurs at the cytoplasmic side of the ER 
membrane. This method can be used in various occasions such as when designing 
constructs for mutagenesis studies or when considering models of multiple proteins in 
a complex. The split-GFP method is not limited to viral proteins but also is applicable 
to cellular proteins as previously shown, which is a bonus. 
 The versatility offered by the split-GFP method extends beyond rapid 
determination of protein topology. As mentioned before, the system can be used in 
live cells in addition to fixed cells (12), meaning high-throughput applications such as 
small interfering RNA (siRNA) screening can be coupled with split-GFP. Indeed, we 
have made attempts to design a siRNA screen to determine host cell proteins 
necessary for VACV morphogenesis. If a viral protein switches its ER-associated 
membrane topology during morphogenesis, a block in the process before the 
transition would yield a different topology when compared to normal conditions. If 
split-GFP tag can be used on that particular protein, then theoretically siRNA 
screening can identify host genes that, when silenced, can prevent the topology 




this purpose, but were unable to acquire their membrane topology with our split-GFP 
method perhaps because of their multiple locations in viral and cellular membranes. 
The size of the GFP-S11 tag is similar to that of small epitope tags and most proteins 
can be tagged with minimal perturbation, which is encouraging in the search for new 
candidate proteins. While trying such high-throughput analysis using split-GFP could 
seem ambitious, it suggests how this method can be modified or combined with other 
techniques to develop innovative strategies for studying VACV morphogenesis. 
 
5.2 Versatile Approaches for Studying Vaccinia Virus Protein I2 
When the role of I2 in VACV entry was suggested (260), we were interested in 
determining the function of I2 in allowing entry of the virus into host cells. The 
possibility of I2 serving as a transporter for other EFC proteins was also considered 
based on the previous report (260) showing 5-fold less EFC protein levels on purified 
virions made under repressed I2 expression. We were therefore surprised by the 
results indicating I2’s role in morphogenesis presented in chapter 4. Yet it had 
allowed another contribution to the understanding of VACV morphogenesis in 
conjunction with studies covered in chapter 3. While L2 and A30.5 (chapter 3) are 
critical for the beginning or early stage of viral membrane morphogenesis, I2 (chapter 
4) has a crucial role in the later stage. Overall, this work has reiterated the complexity 
of virus morphogenesis by highlighting that there still could be unknown proteins 
taking actions in different stages of morphogenesis. 
Prior to this study, the removal of D13 scaffold from the IV membrane was 




turned out that the process is not as simple, however, with I2 also proven to be 
required for the D13 removal. The deletion of I2 therefore blocked the transition from 
IV to MV, yielding defective dense virions that remained spherical and retained D13 
coat. Perhaps I2 could be working as a cofactor of I7, similar to adenovirus protease 
that requires an 11 amino acid cofactor for activation (286-288). In this context, there 
was a reduction of I7 in cells infected with vΔI2. Experiments with I7 repression 
could not demonstrate a similar effect on the EFC protein levels as vΔI2, but a 
deletion-I7L virus may generate more robust evidence for the correlation between I2 
and I7. 
The initial intent of studying virus entry was partially fulfilled as this project 
did not solely focus on the morphogenesis aspects, but also implemented numerous 
experiments with the EFC proteins. Entry protein levels were first analyzed both in 
purified virions and in total cell lysates in the absence of I2. This answered one of the 
questions we had from the beginning of this study, which was about whether EFC 
proteins are inserted into membranes prior to the start of viral membrane formation or 
not. The blockage of EFC protein localization on viral membranes caused by 
retention of D13 scaffold has revealed that EFC proteins are localized after the IV 
formation. The proteins without the accessibility for proper localization were 
degraded, as determined by the pulse-chase experiment. The proteasome inhibitor 
MG132, however, could not stabilize the EFC proteins. MG132 perhaps needed to be 
treated at earlier time point, but 6 hpi had to be used as earlier treatment was reported 
to cause defects in viral replication (289). A question was raised on whether the 




degradation (290) in the absence of I2. Plasmids were constructed to express HA-
tagged A28 and F9 with or without the TM domains, but the experiment was not 
successful as the proteins without TM domains were unstable regardless of I2 
presence (not shown). 
To further characterize the I2 protein a versatile recombinant VACV with a tag 
on I2 was made, and the vGFP-I2 was constructed. It could be used for confocal 
microscopy, immunoprecipitation, mass spectrometry, and immuno-electron 
microscopy. The green fluorescence from GFP-I2 was relatively weaker than that of 
P11 promoter-regulated GFP by naked eye, implicating that I2 naturally has low level 
of expression. Confocal microscopy analysis of GFP-I2 with other viral proteins had 
shown localization of I2 in the viral factories. When stained for I7, GFP-I2 signals co-
localized with the I7 signal. This suggested that I2 might interact with I7, but co-
localization in confocal microscopy alone was not enough to confirm the interaction. 
When GFP-I2 was immunoprecipitated, I7 proteinase was not found despite 
paraformaldehyde cross-linking prior to the immunoprecipitation. Silver staining and 
western blot analysis of the immunopurified samples did show faint signs of 
additional proteins, but mass spectrometry could not show any specific proteins that 
interact with I2.  
When a protein critical for virus replication is absent, it could be interesting and 
sometimes extremely useful to look at the genetic response from the virus. Unlike 
RNA viruses, DNA viruses are generally more stable in terms of spontaneous 
mutations. Infection of RNA viruses such as human immunodeficiency virus (HIV) is 




mutation rates. Poxviruses and other DNA viruses are less mutagenic, and the 
eradication of smallpox would not have been possible if it had higher mutation rates. 
Despite the low mutation rates, poxviruses have their own ways to adapt rapidly to 
unfavorable conditions (282). Although rare, modifications to the genome in forms of 
point mutation, insertion, deletion, gene amplification and genomic accordions have 
been reported (48, 282, 291, 292). Likewise, we wanted to see if VACV could 
eventually compensate the loss of I2L gene through genomic or gene modification as 
this could provide a clue to the function of the protein. We were fortunate to find four 
clones that could replicate without the I2 protein. Whole genome sequencing of the I2 
compensatory mutants showed no amino acid changes but rather duplication and 
triplication of certain regions of the genome. It was expected to find amino acid level 
mutations for proteins such as D13 or I7 that directly correlate to morphogenesis 
defects found in vΔI2, but the genome amplification was equally interesting as it 
suggested the compensation of I2’s role with other gene(s). We first thought the right 
end of the genome was amplified and transpositions into the left side of the genome 
based on the previous case in rabbit poxvirus (48). However, HindIII restriction 
enzyme analysis showed appearance of two additional fragments instead of the 
expected changes in existing fragments. This result suggests that the duplication is 
unstable and that it is continuously deleted so that there is always a mixture of wild 
type genomes and genomes with duplications. While this complicates the genomic 
modification model in our I2 compensatory mutants, it suggests yet another novel 





5.3 Future Directions 
Overall, this work has mainly focused on VACV morphogenesis specifically in 
two areas: the early stage where ER membranes are modified for viral membrane 
formation, and the later stage where IVs mature into MVs. The future directions are 
therefore aimed towards unveiling the mechanism of viral membrane formation as 
well as its transitions. 
 As a follow-up to the split-GFP project, future experiments should focus on 
analyzing the segments or ruptures of the ER membrane regarding how they are 
generated and stabilized. Topological analysis of all the viral membrane proteins and 
cellular proteins with potential function in viral morphogenesis would give a head 
start when modeling protein interactions necessary for the ruptures. Based on 
topology results in chapter 3, mutagenesis of L2 and A30.5 can be done to map 
critical domains for interaction. Furthermore, live cell imaging experiments can be 
used to confirm the breaking of ER membranes. The split-GFP method was used in 
an attempt to see if luminal GFP-S11 tag is released by ER membrane breaks, but was 
unsuccessful presumably because the ruptures are stabilized. ER luminal calcium, 
however, can be more readily released being harder to contain even with a minuscule 
rupture. Live cell imaging studies using fluorescence labeling of calcium and ER 
membrane may be able to provide another evidence for ER membrane ruptures during 
VACV infection. 
 As discussed before, the use of high-throughput siRNA screening using split-
GFP tagged proteins may help to identify host cell proteins necessary for VACV 




defective morphogenesis conditions needs to be identified first. Once such a protein is 
found, it can be tagged with the GFP-S11 tag and separate expression of GFP-S1-10 
within a different compartment will generate a condition where no green fluorescence 
is produced under normal conditions. When morphogenesis is blocked by siRNA 
silencing of certain host mRNA, the GFP-S11 tag could be available for interaction 
with the GFP-S1-10 and give fluorescence. This can be done the other way around 
where it normally gives fluorescence when morphogenesis occurs, but does not when 
morphogenesis is blocked. Identification of host cell protein with a role in VACV 
morphogenesis will be a great step forward in understanding the mechanism. 
There are many additional experiments that could be done to further understand 
the role of I2. We now know why D13 scaffold is not removed and how it causes a 
defect in the late stage of morphogenesis, but the mechanism of I2’s action is not 
known. The correlation between I2 and I7 must be studied in more detail. Only IPTG 
inducible and temperature-sensitive mutants are available for I7, and these could not 
show large differences in EFC protein levels that were expected. Inducible or 
temperature-sensitive mutants are often leaky, which in some cases is enough to alter 
experimental results. A complete deletion I7 mutant could show phenotypes that are 
more dramatic, similar to how the deletion I2 mutant surprised us with the block in 
morphogenesis. Thus, acquisition of the deletion I7 mutant would generate more 
confidence in the analysis of the I2 and I7 mechanism. 
When the function of a protein is unknown, identifying any other interacting 
protein can often provide useful hints. Unfortunately for I2, its interaction with other 




including immunoprecipitation and even mass spectrometry could not show anything, 
but perhaps tagging I2 with HA or V5 tags may produce different results. 
Especially with the difficulties in detecting protein interactions of I2, hopes are 
high on the I2 compensatory mutants for revealing the function of I2. Identifying 
another protein that can replace the role of I2 would be massive. If it is a protein with 
a known function, it should strongly suggest that I2 has a similar function. Even if it 
is not a previously characterized protein, it would be mean that another viral 
morphogenesis protein is discovered. However, the whole genome sequencing 
suggested that the compensatory effect was not from point mutations but from large 
duplications of genome segments. The duplicated/triplicated regions contain 32 
ORFs, and work needs to be done to narrow this list down. Perhaps additional 
passaging of the mutants may naturally select for more narrow modifications, similar 
to the transition from gene accordions to point mutations reported in another study 
(282). The HindIII restriction enzyme analysis requires further experiments as well. 
Isolation of the two additional HindIII fragments in the compensatory mutant 
genomes may enable us to locate the sites where amplified regions have 
transpositioned in the genome. It is likely that the duplication is unstable and that it is 
continuously lost so that there is always a mixture of genomes when there is selection 
pressure. Another novel idea is that the duplicated DNA exists separately outside of 
the viral genome, when under selection pressure from the absence of I2. Maintaining 
such epigenomic DNA is probably less efficient, and removing the selection pressure 




DNA. This type of compensation by non-genomic DNA has not been reported before 
for poxviruses and would be a novel finding if true. 
 A significant amount of work has been put into analyzing EFC protein 
expression in the deletion I2 mutant. We have shown that EFC proteins are subject to 
more rapid degradation when they fail to localize on the viral membrane. Yet the 
mechanism for degradation could not be shown with experiments involving the 
treatment of proteasome inhibitor MG132, detection of ubiquitin, or removal of TM 
domains. Additional proteasome inhibitors may be tested, as well as autophagy and 
lysosome inhibitors. Hydrophobic properties of the TM domains are suspected to 
cause degradation when the proteins are mis-localized, but more experiments are 
needed for confirmation. Our interest in signal sequences is not limited to degradation 
signals. The absence of any known signal sequence within the EFC proteins make it 
difficult to understand how the proteins are transported to the viral membranes. 
Identification of such signals is of a great interest and it can lead to the understanding 
of EFC protein transport mechanism, which will surely benefit the VACV 
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